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Regeneration of large bone defects presents a critical challenge to orthopaedic 
clinicians as the current treatment strategies are severely limited. Tissue engineering has 
therefore emerged as a promising alternative to bone grafting techniques. This approach 
features the delivery of bioactive agents such as stem cells, genes, or proteins using 
biomaterial delivery systems which together stimulate endogenous repair mechanisms to 
regenerate the tissue. Because bone is a highly mechanosensitive tissue which responds 
and adapts dynamically to its mechanical environment, application of mechanical stimuli 
may enhance endogenous tissue repair. While mechanical loading has been shown to 
stimulate bone fracture healing, the ability of loading to enhance large bone defect 
regeneration has not been evaluated.  
The goal of this thesis was to evaluate the ability of sustained osteogenic growth 
factor delivery and functional biomechanical loading to stimulate vascularized repair of 
large bone defects in a rat segmental defect model. First, we evaluated the hypothesis that 
the relationship between protein dose and regenerative efficacy depends on delivery 
system. We determined the dose-response relationship between dose of recombinant 
human bone morphogenetic protein-2 (rhBMP-2) and bone regeneration in a hybrid 
alginate-based protein delivery system and compared with the current clinically-used 
collagen sponge. The hybrid delivery system improved bone formation and reduced the 
effective dose due to its sustained delivery properties in vivo. Next, we tested the 
hypothesis that transfer of compressive ambulatory loads during segmental defect repair 
enhances bone formation and subsequent limb regeneration. We found that delayed 
application of axial loads enhanced bone regeneration by altering bone formation, tissue 
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differentiation and remodeling, and local strain distribution. Finally, we evaluated the 
hypothesis that in vivo mechanical loading can enhance neovascular growth to influence 
bone formation. We found that early mechanical loading disrupted neovascular growth, 
resulting in impaired bone healing, while delayed loading induced vascular remodeling 
and enhanced bone formation.  
Together, this thesis presents the effects of dose and delivery system on BMP-
mediated bone regeneration and demonstrates for the first time the effects of in vivo 
mechanical loading on vascularized regeneration of large bone defects. 
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CHAPTER I: SPECIFIC AIMS 
INTRODUCTION 
 The skeletal system is unique in its capacity for scar-free regeneration after injury 
through the mechanosensitive processes of bone modeling and remodeling, with the local 
mechanical environment determining the course and success of healing [1-2]. Other 
factors that influence the repair process, particularly in situations of challenging trauma 
or disease, include proper biological signals and sufficient vascularization. Like bone, the 
cardiovascular system is also regulated by mechanical conditions, as blood vessels and 
endothelial cells remodel and reorient in response to mechanical stimuli [3-4]. In 
addition, the regenerative processes of osteogenesis and angiogenesis are linked at both 
the cellular and molecular levels, and the responses of bone and vascular cells to 
mechanical conditions have been shown to be co-regulated in vitro [5]. However, despite 
such evidence that the local mechanical environment acutely influences bone healing and 
vascularization, the ability of mechanical stimulation to enhance vascularized large bone 
defect repair has not yet been studied. 
Large bone defects exceeding 3 cm in length represent a particularly challenging 
problem for orthopaedic clinicians [6-7]. The gold standard of care, the autograft, in 
which bone graft particles are surgically transplanted from the patient‟s iliac crest, is 
limited by the available volume of graft material and significant donor site morbidity [8-
9]. Therefore, structural bone allografts are often used clinically to bridge the defects; 
however, a high complication rate is directly attributable to their limited ability to 
revascularize and remodel [10]. Tissue engineering has therefore emerged as a promising 
alternative to grafting techniques. Numerous tissue engineering studies in vitro have 
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demonstrated the importance of the mechanical environment for tissue formation and 
maintenance [11-13]; however, the ability of mechanical loading to enhance tissue-
engineered bone regeneration in vivo has not yet been evaluated. Clinically, fixation of 
segmental defects is typically performed using stiff metal plates that shield the defect 
region from potentially stimulatory loads. By altering fixation stiffness, it may be 
possible to improve clinical treatments of such challenging cases through functional load 
transfer. 
These alterations in mechanical environment may also modulate neovascular 
network formation, which is critical in bone development, growth, and repair. While 
endothelial cells and individual blood vessels respond and remodel to various stress and 
strain profiles [3], the influence of matrix deformations on vascular network growth and 
remodeling in the context of bone repair is not well-known. The overall objective of this 
work was to investigate the role of mechanical stimuli in vascularized bone regeneration 
using customized implant systems designed to allow in vivo actuation. The governing 
hypothesis was that in vivo mechanical loading can enhance bone regeneration and 
vascular growth in large bone defects treated with sustained delivery of rhBMP-2. 
This hypothesis was evaluated in the following specific aims: 
SPECIFIC AIM I 
Determine the dose- and delivery system-dependence of rhBMP-2 in a critically-
sized segmental defect model. Delivery of recombinant human bone morphogenetic 
protein-2 (rhBMP-2) using a hybrid alginate-based delivery system has been shown in 
our lab to induce robust bone formation [14]. This aim evaluated the dose response of 
rhBMP-2 in this nanofiber mesh/alginate delivery system and compared with the current 
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clinically-used collagen sponge to establish a baseline model upon which to test the 
effects of mechanical stimulation. We hypothesized that the relationship between protein 
dose and regenerative efficacy depends on delivery system. 
SPECIFIC AIM II 
Evaluate the effects of in vivo mechanical loading on large bone defect 
regeneration. It is well-known that mechanical factors acutely influence the fracture 
healing process; however, the effects of mechanical loading on large bone defect 
regeneration have not been evaluated. For defects in load-bearing bones, the mechanical 
environment may be varied by altering the stiffness of the fixation plate, allowing transfer 
of ambulatory loads to the regenerating bone. This aim, therefore, compared the effects of 
continuous stiff fixation with electively-actuated compliant fixation that allowed load 
transfer beginning at week 4. We hypothesized that mechanical loading through 
compliant fixation enhances bone defect healing. 
SPECIFIC AIM III 
Evaluate the effects of in vivo mechanical loading on neovascular growth. The 
formation of new blood vessels is essential to provide oxygen and nutrients to 
regenerating tissues and is a primary limiting factor for many tissue engineering 
strategies [15-16]. In bone defect healing, vascular supply may be regulated by the 
mechanical environment. In this aim we evaluated the effects of early and delayed 
loading on neovascular network formation, in comparison with continuous stiff fixation. 
We hypothesized that early mechanical loading inhibits, while delayed loading enhances, 




These aims were evaluated using the critically-sized rat segmental defect model 
developed in our laboratory. In this procedure, a bone segment is surgically removed 
from the rat femur and the remaining fragments are stabilized by a fixation plate which 
spans the defect. Using this model, numerous cellular, biomaterial, biomolecular, and 
biomechanical therapies can be directly and quantitatively compared.  
SIGNIFICANCE 
 This thesis presents the dose-response and delivery system dependence of 
rhBMP-2 delivery in a hybrid alginate-based protein delivery system for bone 
regeneration and demonstrates for the first time that proper application of in vivo 
mechanical loading enhances large bone defect repair by altering bone formation, 
distribution, and tissue differentiation and also regulates vascular growth and remodeling 
to modulate the regenerative response. These observations highlight the importance of 
biomaterial carrier properties in the delivery of recombinant proteins, the influence of the 
biomechanical environment on regeneration, and the sensitivity of neovascular network 
formation and subsequent bone formation to the magnitude and timing of load 
application. Together, these experiments aim to elucidate the mechanoregulatory 




CHAPTER II: LITERATURE REVIEW 
BONE STRUCTURE AND FUNCTION 
Bone serves a number of purposes in human physiology including: (1) a 
repository for calcium, a fundamental element necessary for cellular signaling and 
survival, (2) a vessel for stem cell-rich bone marrow, and (3) a structural framework for 
protecting internal organs and bearing mechanical loads. It adapts dynamically by a 
coordinated network of unique cell types to respond to both metabolic and mechanical 
demands. This tightly regulated turnover allows bone to actively respond to a deficit or 
surplus in soluble calcium and phosphate levels and gives bone a remarkable plasticity in 
response to its mechanical environment. Together, these cells and coordinated regulatory 
mechanisms link structure-function relationships across multiple hierarchical length 
scales.  
Cortical and Trabecular Bone 
At a whole bone level, human bone is divided into two compartments: cortical, or 
compact bone, and trabecular, or spongy bone. Cortical bone is characterized by a dense 
matrix with a relatively low porosity of approximately 10% and makes up 80% of total 
bone mass [17]. In contrast, trabecular bone is made up of numerous interconnected rod- 
and plate-shaped struts which give it a sponge-like appearance and a porosity ranging 
from 50 to 90% [17]. As a result of its low porosity, human cortical bone requires a 
sophisticated microstructure, called the Haversian system, that allows for vascular 
perfusion and waste and nutrient transport as well as a complex network of micro-
tunnels, termed the lacunar-canalicular network, that provides for cross-talk between 
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matrix-embedded and surface-dwelling cells and facilitates transduction of mechanical 
stimuli into biochemical signals which effect cellular activation.  
Bone Cells 
There are three main cell types that regulate bone formation and remodeling. The 
first is the osteoblast, which is responsible for laying down new matrix, called osteoid. 
Osteoblasts are fibroblast-like cells which reside on bone surfaces and are derived 
primarily from the mesenchymal lineage, being replenished by osteogenic differentiation 
of bone marrow stromal cells (also known as mesenchymal stem cells) [18]. Additional 
osteoprogenitor sources such as satellite cells from the surrounding soft tissues or 
vasculature have also been proposed [19-22]. The second bone cell type is the osteoclast. 
Osteoclasts are large multinucleated cells, formed from fusion of cells from the 
monocyte/macrophage lineage, and are responsible for bone matrix resorption through 
excretion of H
+
 ions through V-type ATPase proton pumps and Na/H antiporters [18]. 
Osteoblasts and osteoclasts communicate and regulate bone turnover through feedback 
mechanisms involving receptor activator of NFκB ligand (RANKL) and osteoprotegerin 
(OPG), which regulate osteoclast activity and osteoblast activation[18]. The third cell 
type is the osteocyte. Osteocytes are the most abundant cell type in bone, and are derived 
from differentiation of matrix-embedded osteoblasts [18]. Mature osteocytes are stellate 
shaped and feature large numbers of cytoplasmic processes that allow interactions 
between neighboring osteocytes through gap junctions [23]. Osteocytes reside within the 
bone matrix in small pockets called lacunae. These lacunae are connected to one another 
via canaliculi that allow cross-talk between osteocytes and communication with both 
osteoblasts and osteoclasts [24]. Osteocytes have been implicated as the master control 
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cells in bone which regulate matrix deposition and resorption by osteoblasts and 
osteoclasts, respectively [25-27].  
Bone Matrix 
On a nanostructural level, bone is made up of both mineral and organic phases, 
and unlike most other tissues, the matrix is primarily comprised of inorganic mineral (70-
90%), which consists of hydroxyapatite, a calcium phosphate apatite whose molecular 
composition is: Ca10(PO4)6(OH)2 [28-29]. These mineral deposits are situated along or 
between the proteins of the organic phase [28]. Approximately 95% of the organic phase 
of bone matrix is type I collagen, with the remainder comprised of proteoglycans such as 
decorin and biglycan and other non-collagenous proteins including glycoproteins such as 
osteopontin, fibronectin, and bone sialoprotein [18]. Many of these proteins feature both 
structural and functional roles, modulating tissue properties as well as cellular adhesion, 
migration, proliferation, and differentiation [28]. Osteopontin, for example, is a 
phosphorylated glycoprotein expressed by all of the various bone cell types, and is 
implicated as an important signaling molecule in the early stages of osteogenesis by 
modulating adhesion of osteoblasts to the extracellular matrix as well as in osteoclast 
attachment and function [18, 30].  
BONE DEVELOPMENT 
During development, the long bones, such as those in the extremities, form 
through a process termed endochondral ossification, in which bone formation occurs via 
a cartilage template, which is subsequently vascularized and then remodeled by 
osteoclasts/chondroclasts and replaced with bone by osteoblasts. In endochondral bone 
formation, the processes of chondrogenesis, osteogenesis and angiogenesis are linked at 
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the molecular, cellular, and tissue levels, and disruption of any one results in altered limb 
formation and defects in the other two processes [5]. For example, many of the genes and 
signaling molecules important for the genesis of cartilage, bone, and vasculature, such as 
Indian Hedgehog (Ihh), Runx2, and VEGF, respectively, are shared such that knock-out 
animals lacking any of these three genes experience defects in each of the three tissues 
[5].  
Flat bones, conversely, such as those of the skull, form through intramembranous 
or direct bone formation, in which mesenchymal cells differentiate directly down an 
osteoblastic lineage and bone is appositionally laid down without the use of a cartilage 
scaffold [31]. In both processes, newly formed woven bone is progressively remodeled to 
mature, lamellar bone. Woven bone is characterized by disorganized, randomly-oriented 
collagen fibrils, while in lamellar bone, the collagen is highly organized into parallel 
arrays that alternate in longitudinal and transverse patterns, giving bone its orthotropic 
material symmetry [31]. 
BONE REMODELING 
Bone has a remarkable ability to adapt to its functional environment, such that its 
material properties and geometric features are continuously optimized to withstand 
applied loads [32]. For example, peripheral quantitative computed tomography (pQCT) 
scans of humerae of elite tennis players indicated a significant 26% increase in cortical 
cross sectional area in the humerus of the playing arm over the contralateral limb [33-35]. 
The mechanisms by which this regenerative and adaptive process occurs have only 
recently begun to be elucidated. The cellular players responsible for bone tissue 
remodeling were first systematically described in the early 1960‟s by Frost, who 
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demonstrated that modeling and remodeling are mediated by basic multicellular units 
(BMU), made up of osteoblasts, osteoclasts, and osteocytes [36-39]. Osteoblasts lay 
down bone matrix and osteoclasts degrade it within a highly regulated and interconnected 
milieu of biochemical signals. Osteocytes, residing within bone matrix and 
communicating with other cells through the lacunocanalicular network, are thought to be 
the primary mechanosensors that transduce mechanical stimuli into chemical signals [32, 
40]. The adaptive activity of these BMUs is stimulated by changes in the mechanical 
loading history. Frost hypothesized that this mechanical mediation of bone remodeling 
was regulated by an inherent “mechanostat” such that there is a window of strain stimuli 
that maintains bone mass, below which the tissue is resorbed, and above which induces 
bone formation [41]. Frost hypothesized that the set-points for bone resorption and bone 
formation are approximately 100-300 microstrain and 1500-3000 microstrain, 
respectively [41]. 
Turner and others have since studied numerous mechanical variables affecting 
bone adaptation [42-46], and have proposed three rules for load-induced adaptation [47].  
First, bone adapts to dynamic, but not static strains. Experimental observations revealed 
that the strain stimulus, or the strain needed to induce adaptation, was proportional to 
both strain magnitude and frequency: 
 fkE 1  , Eqn. 2.1 
where E is the strain stimulus, k is a proportionality constant, ε is the peak-to-peak strain 
magnitude, and f is the loading frequency [46]. Second is the principal of diminishing 
returns, that is, as loading duration is increased, the bone formation response tends to 
level off. This effect was mathematically described by Carter and colleagues as: 
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12    , Eqn. 2.2 
where k2 is a constant, N is the number of loading cycles per day, σ is the effective stress, 
and m is a constant weighting-factor, which has been estimated at 3.5-4, based on 
published data [47-48]. Finally, bone adaptation is error-driven such that bone cells 
accommodate to “normal” strain waveforms, but adapt to abnormal strain changes [49]. 







 , Eqn. 2.3  
where M is bone mass, t is time, φ is the local stress/strain state, and B and F are 
constants that describe the “normal” load state [50]. Thus, φ – F represents the error 
function driving bone mass adaptation. 
 These rules apply to both mechanical stimulation of new bone formation, and 
disuse-induced bone resorption. Astronauts, for example, experience significant 
reductions in bone mass: when the local stress/strain state, φ, becomes less than the 
normal earth-bound state, F, because of reduced gravitational loads, the negative error 
function drives bone resorption [51]. This tightly-regulated system can also become 
pathogenic in osteoporosis, in which the communication between constituents of the 
BMU is disrupted, and more bone is resorbed than can be replaced, leading to decreased 
bone mass and skeletal fragility. 
BONE MECHANOTRANSDUCTION 
The study of the cellular mechanisms underlying these adaptive phenomena is an 
active area of investigation. Initially, osteocytes were thought to be biologically 
quiescent; however, their abundance, distribution and extensive interconnectedness 
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through gap junctions uniquely situates osteocytes to act as mechanosensors [40]. These 
cells may therefore act as amplifiers that take in a variety of mechanical stimuli and 
signals to coordinate a tissue-level adaptive response. The intercellular process of 
converting mechanical stimuli into biochemical signals resulting in coordinated 
adaptation is termed mechanotransduction. Duncan and Turner described this process in 
terms of four distinct steps: (1) mechanocoupling, (2) biochemical coupling, (3) signal 
transmission, and (4) effector cell response [52].  
The first step of mechanotransduction, mechanocoupling, involves the 
transmission of forces/deformations from the surrounding bone matrix to the cell. Several 
mechanisms of mechanocoupling have been proposed, and it is likely that all of them act 
in concert to result in the biochemical, cellular, and tissue-level changes associated with 
bone adaptation. Perhaps the most direct possibility is matrix-associated mechanical 
strain of an osteocyte. In vivo, bone matrix strains reach up to approximately 0.3%; 
however, in vitro studies of the effects of mechanical stretch on bone cells and cell lines 
have found that variable gene expression is not activated until approximately 3% cell 
strain, a full order of magnitude larger than that found in vivo [24, 53-54]. This suggests 
that other amplification mechanisms may play a role in mechanocoupling. Possibilities 
include shear forces caused by fluid flow through canaliculi [55], intramedullary pressure 
[56], transient pressure waves [57], and dynamic electric fields, known as streaming 
potentials [24, 32, 40]. Overall, the various effects of lacunar-canalicular fluid flow have 
been suggested to be the most probable mechanism of mechanocoupling [55, 57-62]. 
Recently, Price et al. demonstrated experimentally that bone loading significantly 
increases solute transport and fluid flow in the lacunar-canalicular system (LCS) under a 
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loading regime known to induce large scale bone adaptation [55]. This load-induced fluid 
flow also induces streaming potentials caused by the convective transport of charged 
solutes present in LCS fluid [56, 58]. Other amplification mechanisms have been 
proposed as well. For example, Han and colleagues have suggested that the large flexural 
rigidity of the osteocyte cell processes result in strain amplification [63]. Which 
mechanism is most important is difficult to determine as it is challenging to 
experimentally isolate these various effects, and it is likely that they combine in vivo to 
yield the observed results. 
The second step in the mechanotransduction process is biochemical coupling. In 
this stage, the various mechanical stimuli experienced by a cell are converted to 
biochemical signals. Numerous signaling pathways have been shown to be activated by 
mechanical loads, initiated through coupling factors at the cell membrane. Proposed 
mechanisms include force transfer through integrins and/or focal adhesions and the 
cytoskeleton, stretch-activated ion/cation channels in the cell membrane, deformation of 
extracellular flagella known as primary cilia, and membrane structure alterations due to 
lipid raft and calveoli reorganization [32]. 
For example, blocking of G protein-coupled receptors has been shown to 
eliminate up to 80% of prostaglandin production in osteocytes under fluid shear [64]. 
Also implicated in this pathway are stretch-activated cation channels in the cell 
membrane, particularly those involving calcium signaling [65-68]. Recently, Guo and 
colleagues demonstrated the importance of T-type voltage-activated calcium channels in 
regulating the kinetics of calcium influx in osteocytes following exposure to fluid shear 
stress [69]. Mechanical stimuli have also been shown to recruit integrins to focal 
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adhesions in numerous cell types, including both osteoblasts and osteoclasts, resulting in 
reorganization of actin filaments into stress fibers and activation of focal adhesion kinase 
[64, 70-71]. Bone cells also possess solitary (primary) cilia that deflect in response to 
fluid flow and which mediate upregulation of various osteogenic signals including 
prostaglandin and osteopontin [72-73]. Other membrane structure alterations involving 
the small lipid rafts known as calveolae have been shown to activate intracellular 
signaling cascades in response to cell deformation [74-76].  Together, these coupling 
mechanisms link external loads to internal biochemical signals, though many questions 
remain.  
The third step in mechanotransduction is signal transmission, in which 
intracellular signaling cascades are activated to bring about alterations in gene expression 
and protein synthesis and activity. Mechanical stimuli activate numerous signaling 
molecules and cascades, and many of these are shared across various cell types including 
monocytes, fibroblasts, endothelial cells, chondrocytes, osteocytes, and osteoblasts [32]. 
These pathways include the canonical Wnt pathway which regulates the degradation and 
activity of β-catenin, non-canonical Wnt signaling, integrin signaling through FAK and 
other receptor tyrosine kinases, NO and cGMP/PKG signaling, and various G-protein 
coupled receptor pathways including the cAMP activation of PKA, PLC processing of 
PIP3 into IP3 and DAG to stimulate intracellular Ca
2+
 signaling and PKC activity as well 
as the MAPK cascades and PI-3K activation of PKB.  
Canonical Wnt signaling through the β-catenin pathway has recently received 
great interest as a mechanotransduction mechanism [77]. Intracellular β-catenin is 
normally controlled by binding to a “destruction complex,” containing glycogen synthase 
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kinase (GSK-3β) [78]. Under mechanical stimulation, cells produce small molecules 
known as Wnts that bind to the membrane receptor complex of LRP5/6 and Frizzled to 
phosphorylate GSK-3β, resulting in deactivation of the destruction complex [79-80]. This 
allows stabilization of intracellular β-catenin, which translocates to the nucleus to initiate 
gene expression and in osteoblasts, for example, induces bone formation [81-82]. 
Interestingly, mechanical stimulation of osteocytes has also been demonstrated to activate 
the β-catenin pathway independently of Wnt signaling through nitric oxide (NO) and 
phosphatydilinositol-3 kinase (PI3-K) [83]. In vivo, mice deficient in the transmembrane 
receptor LRP5 fail to adapt to an anabolic ulnar loading regime, demonstrating the 
importance of the pathway in functional bone adaptation [84]. 
Similarly, non-canonical, β-catenin-independent Wnt signaling is also sensitive to 
the mechanical environment through integrin-mediated activation of the GTPase RhoA, a 
critical mediator of actin stress fiber assembly [85]. Recently, Khatiwala and colleagues 
demonstrated that RhoA and the Rho-associated protein kinase (ROCK) differentially 
activate the extracellular related kinase (ERK) to stimulate osteogenic Runx2 gene 
expression through the MAPK cascade in response to changes in extracellular matrix 
compliance [86]. 
Other integrin-mediated signaling cascades have been shown to be upregulated by 
extracellular mechanical conditions. One such pathway is G protein-coupled receptor 
activation of cAMP signaling [87]. Osteoblasts have also been shown to undergo 
extensive cytoskeleton reorganization in response to both cyclic hydraulic pressure and 
fluid shear stress, resulting in changes in cell stiffness and cyclo-oxygenase (COX2) gene 
expression and ATP production [88]. This process is dependent on the focal adhesion 
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protein α-actinin, which is necessary for stress fiber formation and subsequent COX2 
production in osteoblasts exposed to fluid shear stress [89]. 
Other important signaling cascades in mechanotransduction include the PI-3K and 
protein kinase B (PKB/Akt) axis and phospholipase C (PLC) activation of intracellular 
calcium release mediated by inositol-3 phosphate (IP3) and diacyl-glycerol (DAG) [90-
91]. For example, Yang et al demonstrated that mechanical strain of osteoblasts results in 
phosphorylation of the receptor tyrosine kinase PDGFRα to stimulate matrix 
metalloproteinase expression through PI-3K and PLC [90]. This same signaling cascade 
has also been shown to upregulate ERK1/2 signaling in osteoblasts in a Ca
++
 dependent 
manner through the L-type voltage-sensitive calcium channels [91]. Further downstream, 
fluid shear stress-induced Ca
++
 release causes translocation of nuclear factor κB (NFκB) 
into the nucleus to induce COX2 gene expression [92]. In parallel, ERK1/2 activity 
causes mitogen activated protein kinase cascades involving p38 and c-Jun related kinase 
(JNK) [93-94]. These numerous and overlapping signaling cascades converge to provide 
these cells with remarkable specificity and sensitivity to their mechanical environment. 
The final step in mechanotransduction is effector cell response, in which the basic 
multicellular units communicate to bring about the desired response. These 
communications occur directly through gap junctions and by diffusion of secreted signals 
such as NO [32]. The ultimate response of the BMU is dependent not only on the 
instantaneous mechanical environment, but also the stress/strain history, as cyclic loading 
is more stimulatory than single or isometric loads and long durations of loading or 
unloading may shift the mechanostat setpoint [52]. Overall, mechanical and biochemical 
regulation of bone remodeling have received much attention because of their influence on 
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the etiology of osteoporosis and other metabolic bone diseases as well as their importance 
in bone healing and regeneration.  
BONE FRACTURE HEALING 
 Many of the molecular mechanisms and tissue differentiation profiles seen during 
fetal development have been shown to be recapitulated in bone fracture repair. As in bone 
development, bone repair can occur through both the endochondral and intramembranous 
pathways. Endochondral repair features cartilaginous callus formation followed by 
remodeling and replacement with bone, and occurs in the presence of compressive 
micromotion. Endochondral fracture repair begins with haematoma formation following 
injury, which forms a fibrinous clot that serves as a scaffold and a growth factor supply to 
facilitate cell migration and reparative function [31]. The early stages of fracture healing 
(within the first 24 hours) are characterized by an inflammatory phase that has been 
shown to be necessary for proper healing [95]. This is followed by osteoprogenitor cell 
migration and differentiation to develop the fracture callus over the first week after 
injury. These cells potentially come from three sources: the periosteum, the surrounding 
soft tissues, and the marrow space within the bone [96]. The periosteum is commonly 
considered to be the primary source of osteo/chondroprogenitors [96-98], though the 
potential of intramuscular implantation of demineralized bone to induce ectopic bone 
formation [99] and the ability of bone marrow stromal cells to undergo osteogenic and 
chondrogenic differentiation [100-101] suggest that the surrounding tissues and the 
endosteal bone marrow also play important roles in the repair process [96]. Upon arrival 
at the fracture site, these cells differentiate and begin formation of the cartilaginous callus 
that characterizes endochondral bone formation. This avascular callus formation serves to 
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stabilize the fracture gap and reduce interfragmentary motion, and allows for growth of 
vasculature into the callus from the periphery at around 2 weeks after injury [31, 96]. 
This facilitates rapid woven bone formation, chondrocyte apoptosis, and 
osteo/chondroclast recruitment to completely replace the cartilage template with 
disorganized woven bone (Figure 2.1). Finally, in the third week after injury and 
following, the external callus is resorbed by osteoclasts, the disorganized woven bone is 
replaced by mature lamellar bone and the marrow is reestablished [96].  
 
Figure 2.1. Histological images of endochondral ossification during bone repair.  (A): 
Haematoxylin and Eosin-stained section showing hypertrophic chondrocytes, woven 
bone formation (b) and vascular invasion (arrow indicates erythrocytes). (B): Safranin-O-
stained section showing glycosaminoglycan matrix (red) around hypertrophic 
chondrocytes (c).  Images at 63x. 
 
MECHANICAL STIMULATION OF BONE HEALING 
 Each stage of this process is highly sensitive to mechanical conditions, which 
have the potential to both accelerate and improve fracture repair as well as induce 
delayed healing or nonunion [1, 102-126]. The early stages of repair including 
haematoma formation, cellular recruitment, and initial tissue differentiation have been 
shown to particularly sensitive to mechanical stimuli [105, 109, 124].  
The optimal mechanical environment for rapid and effective fracture healing 






shown to affect fracture healing, including load magnitude [102-103, 111, 127], timing 
[105, 113-114, 126], frequency [127-130], cyclic vs. constant application [121], rate 
[131], and loading mode (i.e. direct shear [112, 118, 120], torsion [112], compression [1, 
103-104, 106, 108, 111, 115, 122-123, 125, 132-135], tension [119, 134-138], and 
bending [102, 125, 139-140]). Other studies have differentiated the effects on healing 
progression in terms of the stress/strain invariants, that is, the hydrostatic and deviatoric 
stresses/strains [141-142].   
It is now well-accepted that moderate levels of compressive interfragmentary 
strain are anabolic to callus formation and subsequent healing [1, 115]; however, the 
effects of tension and shear remain controversial. In distraction osteogenesis, a technique 
pioneered by Gavril Ilizarov in the 1950‟s, the bone fragments are distracted at 
approximately 1mm/day, resulting in osteogenesis and ultimately limb lengthening [134]. 
In this method, the applied tensile stresses induce primarily intramembranous bone 
formation [143], though formation of cartilage has been observed in some studies [137, 
144]. The Ilizarov technique has been used extensively and successfully in the treatment 
of limb length disparities, and in the healing of some nonunions and bone defects [145]. 
In contrast, application of cyclic tensile stains, without progressive lengthening has 
yielded conflicting results, with some studies showing little to no beneficial effect and 
others indicating a deleterious effect [119, 135]. The effects of shear are similarly 
ambiguous, with some studies showing drastic inhibition of healing, to the point of 
causing nonunion [110, 112, 120, 124] while others have shown positive effects [118]. 
These differences are likely due to differences in shear strain magnitude, timing, fixation 
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device, and animal model. Further research is warranted to determine the importance of 
biomechanical conditions in bone repair.  
Several groups have attempted to synthesize these various data into 
mechanobiological theories that describe the tissue differentiation patterns under different 
mechanical environments. Pauwels, for example, distinguished between the volume 
changing effects of hydrostatic stresses and the “distortional” octahedral shear stresses 
which induce shape change without altering volume [141]. From studying tissue 
differentiation patterns in pseudarthroses and angulated fractures, he concluded that 
hydrostatic stresses specifically induce cartilage formation, while the deviatoric stresses, 
which by necessity feature tension in some direction, cause collagen fiber development 
[141, 146]. Perren [147] and Perren and Cordey [148], basing their differentiation theory 
on local strain magnitude, rather than stress invariants, proposed the “interfragmentary 
strain theory,” which states that following fracture, differentiation will occur to produce a 
tissue which has a higher ultimate strain than the current interfragmentary strain. As 
tissues grow in and increase the stiffness of the fracture gap, the interfragmentary strain is 
reduced, allowing further differentiation into a tissue with a lower failure strain and 
higher modulus. Thus, following fracture, the tissues differentiate from granulation 
tissue, which features a low stiffness but high ultimate strain, to cartilage, to 
fibrocartilage, and finally is remodeled to bone, which is characterized by a low ultimate 
failure strain, but a high modulus of elasticity that limits deformation and confers a high 
toughness to withstand transient loads [148].  
 More recently, Carter and colleagues have combined and expanded upon these 
theories to relate tissue differentiation to mechanical loading conditions and history 
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[146]. They suggest that tissue differentiation profiles are related to the cyclic load 
history of both the principal tensile strains and hydrostatic stresses. For example, 
fibrocartilage differentiation is preferential in regions of high tensile strains with 
superimposed compressive hydrostatic stress, while bone formation occurs in regions of 
relatively low tensile strain and low hydrostatic stress [146]. It is important to note that 
these profiles are also highly dependent on local biochemical signals and oxygen tension. 
In an adverse biological environment, or in hypoxic conditions, for example, bone 
formation may not occur despite stimulatory mechanical conditions. To date, however, 
the most desirable stress/strain history for bone repair remains unknown, and must 
account for the complicated biological events associated with the different stages of bone 
healing, including haematoma formation, cell proliferation, and vascularization. 
 While appropriate levels of mechanical stimuli can play a positive role in bone 
healing, excessive loading or instability may delay or even prevent successful bone union 
[110, 149]. These considerations are important when designing and implementing 
fracture fixation devices, and may be equally valuable in the treatment of large bone 
defects, which like fracture non-unions fail to heal without further intervention.  
BONE DEFECTS & CLINICAL NEED 
Large bone defects exceeding 3cm in length, caused by high-energy trauma, fracture 
nonunion, or tumor resection, represent a particularly challenging problem for 
orthopaedic clinicians [6-7]. It is estimated that more than 500,000 bone grafting 
procedures are performed annually in the US and 2.2 million worldwide [150]. These 
represent an annual cost of $2.5 billion per year in the US alone [150]. The clinical gold 
standard of care is implantation of morselized autograft bone, taken from the patient‟s 
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iliac crest; however, this treatment is restricted by lack of mechanical integrity, 
significant donor site morbidity and limited graft availability [8-9]. To overcome these 
limitations, structural bone allografts are often used clinically to bridge the defects; 
however, a high complication rate is directly attributable to their limited ability to 
revascularize and remodel [10, 151-154]. Another concern with allograft treatment is risk 
of disease transmission, which, despite rigorous sterilization efforts, has been reported as 
recently as 2002 [155-156]. Together, these limitations have stimulated great interest in 
the development of bone graft substitutes, and tissue engineering has emerged as a 
promising alternative. In recent years, several tissue engineering strategies have been 
approved by the US Food and Drug Administration (FDA) for clinical application 
including various biomaterial scaffolds and several growth factors [157-158].  
BONE TISSUE ENGINEERING 
A tissue engineering approach which shows particular promise involves 
recapitulating or stimulating endogenous repair mechanisms to capture the body‟s innate 
capacity for self-renewal. The repair of challenging large bone defects is an attractive 
application of this strategy as bone tissue, unlike most soft tissue injuries, possesses an 
intrinsic capacity for scar-free regeneration, given proper mechanical and biochemical 
conditions.  
Biologics 
One such strategy is the delivery of osteogenic or angiogenic biologics. These can 
be small molecules, genes, proteins, stem cells, or terminally-differentiated cells. Small 
molecules are attractive as many may be synthetically synthesized in large amounts with 
high purity at relatively low cost [159-160]. One such example which shows great 
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promise in bone repair is desferrioxamine (DFO), which acts as a prolyl-hydroxylase 
inhibitor to stimulate the hypoxia inducible factor-1α (HIF-1α) pathway, an upstream 
regulator of the potent angiogenic growth factor, vascular endothelial growth factor 
(VEGF) [159-160]. Another method is delivery of genes which stimulate endogenous 
cells to differentiate or produce growth factors [161-162]. For patients with depleted 
numbers or reduced activity of endogenous cells, stem and differentiated cell delivery is a 
promising strategy [101, 163-164]. While there has been much attention placed on the 
possibility of inducing stem cells to reconstitute a tissue defect, and many studies have 
shown a beneficial effect of such treatments, the cells frequently fail to become engrafted 
in the regenerate tissue [101]. This has led to the idea of using stem cells as 
programmable factories and delivery vehicles for target proteins. In this approach, the 
cells are not necessarily expected or desired to integrate into the functional tissue, but 
rather to provide the factors necessary for endogenous regeneration in a physiologically 
relevant manner. Finally, a much-studied and clinically successful strategy is the delivery 
of recombinant growth factor proteins. While dose and delivery requirements must be 
tailored for various applications and implant sites, this approach is one of the most 
successful tissue engineering strategies to date [165]. 
The introduction of osteoinductive agents as a potential strategy for bone 
regeneration dates back to Marshal Urist‟s seminal discovery in 1965 of the potential of 
devitalized, decalcified allografts to induce bone formation in both ectopic and orthotopic 
sites [99]. Urist and others subsequently extracted and identified the active biological 
agents, the bone morphogenetic proteins (BMPs), of which there are at least 15 known 
types, and which belong to the transforming growth factor-β (TGF-β) supergene family 
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[166-170]. Identification of the genetic sequence of BMP-2 by Wozney and colleagues 
enabled mass manufacture of highly purified BMP through recombinant gene technology, 
which has facilitated its use as a clinical therapy [8, 157, 166, 171].  
The BMPs are some of the most important growth factors in bone development, 
post-natal bone formation, and repair [172-174]. BMP-2, 4, and 7 are all known to play 
critical roles in bone healing through stimulation of mesenchymal cell differentiation 
down osteogenic pathways [157]. For example, mice deficient in these proteins develop 
with significant skeletal abnormalities [175]. The BMPs, like all members of the TGFβ 
supergene family, bind to serine-threonine kinase receptors. BMP signaling occurs 
through both type I and type II TGFβ receptors [176-178], and are transduced primarily 
through the Smad signaling pathway [175-176]. However, MAPK pathways have also 
been implicated in BMP signal transduction [175-176]. Downstream of BMP binding, 
several transcription factors are activated, the most-studied of which is the Runt-related 
transcription factor-2 (Runx-2), a master-regulator of osteoblastic differentiation of 
mesenchymal cells [175, 179-181]. These mechanisms give the BMPs remarkable 
potential as therapeutic agents. To date, two of the BMPs have been approved by the 
FDA for use in humans: rhBMP-2 and rhBMP-7, also known as human osteogenic 
protein-1 (hOP-1) [182].  
Despite robust responses to both rhBMP-2 and rhBMP-7 in numerous animal 
models, results of clinical trials in human patients have not been as impressive, likely as a 
result of shortcomings in current delivery methods or lack of sufficient numbers of native 
responding cells [182]. The FDA-approved and commercially available rhBMP-2 
product, Infuse®, from Medtronic, consists of a large dose (3.5 to 12 mg) of soluble 
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protein, injected onto a bovine collagen I sponge prior to implantation [183]. This 
delivery system yields a bolus dose with fast release kinetics and may result in protein 
degradation prior to effective interaction with host cells, suggesting that sustained-release 
delivery systems may improve efficacy in humans [157]. 
Biomaterials 
Numerous biomaterials are under investigation today as bone tissue engineering 
scaffolds and biologic delivery systems including biodegradable polymers, bioactive 
ceramics, and permanent or non-resorbable scaffolds. Natural polymers exhibit good 
cytocompatibility and bioactivity; however, they may be immunogenic, their degradation 
rates are difficult to modify, and they generally have low mechanical properties. Natural 
materials used for bone tissue engineering include demineralized bone matrix (DBM), 
type I collagen [184], fibrin [185], chitosan [186-187], and silk [188-189]. DBM and type 
I collagen have both been used clinically to treat craniofacial defects and to perform 
spinal fusions [190-191]. 
Synthetic polymers have the advantage of being chemically engineered to possess 
minimal danger of immunogenicity or disease transmission as well as improved control 
of degradation rate, mechanical strength, porosity, and microarchitecture [192]. García 
and colleagues have shown improved cell adhesion to synthetic scaffolds through 
adsorption of extracellular matrix proteins such as fibronectin or presentation of bio-
adhesive motifs (i.e. GFOGER) on biomaterial surfaces [193-194]. Poly-α-hydroxy esters 
such as PLA, PGA, and their co-polymers have received heavy attention due to their 
common use in clinical practice as suture and fixation implant materials [195-196], 
though some inflammatory response has been observed due to their bulk resorption 
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kinetics and acidic degradation products [197]. Poly(ε-caprolactone) (PCL) scaffolds 
have the advantage of easy manufacture through rapid-prototyping techniques and have 
been FDA approved for clinical use in the healing of critically-sized cranial defects; 
however, degradation is very slow and cell adhesion poor [198]. Scaffolds of 
polyanhydrides and poly(propylene fumarate) have been developed to be conformal 
filling, that is, they crosslink in situ into porous three-dimensional constructs, allowing 
conformation to complex geometries. These injectable scaffolds must be designed for 
minimal heat release during solidification to mitigate damage to surrounding or delivered 
cells [199-200]. 
A tremendous amount of research has been performed on biocompatible ceramic 
materials that mimic the mineral phase of bone. Ceramic scaffolds provide an 
osteoconductive surface and have specifically been shown to encourage absorption of 
bioactive proteins [201], promote vascular ingrowth [202], and foster osteoblast 
adhesion, growth, and differentiation [203-204]. This class of scaffold materials offers a 
range of resorption rates, but they are often characterized by poor fracture toughness and 
mechanical strength, especially in porous forms, making them ill-suited to load-bearing 
situations [205]. Clinically, 45S5 Bioglass® is successfully used to treat periodontal 
disease, as a bone-filler material, and to replace damaged middle ear bones [205-206]. 
Porous cements made of calcium phosphates such as β-tricalcium phosphate (β-TCP) are 
often used as bone void fillers and have been used clinically to repair craniofacial defects 
[207-209].  Although these scaffolds often exhibit monotonic stiffness and strength 
similar to bone, mechanical properties relevant to cyclic functional loading such as 
fracture toughness and fatigue resistance are typically unacceptably low due to limited 
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ability to arrest crack propagation [210]. Hydroxyapatite (HA) is a biocompatible ceramic 
with similar chemical composition to the mineral phase of bone which is used clinically 
for craniofacial defect repair, and as a coating for femoral components of hip 
replacements in humans [210]. Coralline HA, derived from sea coral, has been used 
clinically in spinal fusions as well as management of fractures of the tibial plateau [211-
212].  A recent study comparing the performance of different porous ceramic scaffolds in 
vivo found that biphasic calcium phosphate and TCP scaffolds showed better 
osteoconduction than HA scaffolds in a goat spinal fusion model [213].  
Ceramic scaffolds feature osteoconductivity and bioactivity but are limited by 
brittleness, incomplete interconnectivity, slow degradation rates, and relatively low 
porosity. Conversely, synthetic porous polymer scaffolds typically offer more 
controllable architecture but, alone or unmodified, typically present a poor interface for 
cell attachment and mineralized matrix synthesis. Composite scaffold materials may 
therefore provide the opportunity to combine the best features of ceramics and polymers 
and achieve better performance than can be provided by single phase scaffolds. A 
common strategy has been to incorporate ceramic particles into natural or synthetic 
polymer matrices [198, 214-218]. In addition to potentially improving mechanical 
properties, composite scaffolds improve bone cell adhesion and accelerate resorption due 
to an increase in surface area available for hydrolysis. 
 Optimizing scaffold design for growth factor delivery requires an additional set of 
design criteria. Important factors include the protein release kinetics, protein binding 
affinity, released protein bioactivity, capacity for adhesion and migration of endogenous 
cells, and degradation rate and by-products. Different materials and conformations 
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provide varying degrees of control of these considerations. For example, Griffith and 
colleagues have tethered growth factors to biomaterial substrates to regulate 
spatiotemporal protein presentation to mesenchymal stem cells and hepatocytes [219-
221], and Phelps et al. covalently linked PEG hydrogels with VEGF and cell adhesive 
peptides to enhance vascular network formation in vivo [222]. Others, such as Stayton 
and Mooney, have focused on modifying the degradation properties of various hydrogels 
to modulate growth factor delivery [223-224], while Johnson and colleagues instead used 
biomaterials to modulate the degradation kinetics of the proteins themselves (Johnson et 
al in press CORR). These inexhaustive examples illustrate the variety and power of the 
biomaterial delivery approach; however, degradation properties, release kinetics, and 
other material properties must be designed and tailored for application as well as implant 
site, and the optimal delivery methods for growth factor-mediate bone regeneration have 
not yet been determined [165, 225].  
This thesis will employ an alginate hydrogel developed by Mooney and 
colleagues for use as a spatiotemporal BMP-2 delivery vehicle [226-227]. Alginate is a 
natural polysaccharide derived from brown algae which may be functionalized with 
adhesive motifs and irradiated to decrease molecular weight and modulate degradation 
kinetics [224, 227]. This work will use a method developed in our laboratory by 
Kolambkar et al., in which the growth factor-loaded alginate is injected into the defect 
after a biodegradable PCL mesh is wrapped around the native bone ends to contain the 




 Mechanical stimulation is another emerging strategy for enhancing regeneration 
in tissue-engineering. In bone fracture healing, it is clear that the mechanical environment 
acutely influences regeneration, and these principles are now being applied to tissue-
engineered bone repair, both in vitro and, in this thesis, in vivo. Bioreactors, which allow 
culture of cells and constructs in both 2- and 3-dimensional environments, have been 
developed to investigate the influence of fluid shear stress and mechanical strain in vitro. 
These systems have been used to demonstrate the sensitivity of bone cells [229-232], 
intact tissue explants [233-234], and tissue-engineered constructs [11-12, 235-239]. In 
general, mechanical stimulation enhances osteogenic differentiation and matrix 
production in osteoblast precursors and mature bone cells, and may enhance cell viability 
and matrix distribution in tissue-engineered constructs. Duty et al. have confirmed these 
effects in MSC-seeded scaffolds loaded in vivo in the hydraulic bone chamber model 
[13]. Together, these data implicate mechanical loading as a potential method for 
stimulating endogenous repair mechanisms in tissue-engineered bone regeneration.  
However, the ability of mechanical loading to enhance large bone defect regeneration has 
not yet been evaluated. 
BLOOD VESSELS & ANGIOGENESIS 
Structure and Function 
A key component of bone formation, remodeling, and repair is the ability to 
develop and maintain sufficient vascular supply. Blood vessels carry oxygen, nutrients, 
growth factors, and circulating cells, and due to the low diffusivity of the dense bone 
matrix, proximity to capillaries is essential for bone viability and regeneration [15]. 
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Arterial vessels consist of three layers, the intima, the media, and the adventitia. The 
intima is the innermost layer of the arterial wall, and features a continuous layer of 
endothelial cells that line the vessels [240]. The next layer, the media, is a “porous 
heterogeneous medium” which contains an extracellular matrix phase of collagen and 
elastin fibers embedded with smooth muscle cells, and is responsible for the distensibility 
of the vessels [240]. The final layer, the adventitia, connects the vessel to the surrounding 
matrix and consists of primarily fibrous connective tissue and a sparse distribution of 
fibroblastic cells [240]. This structure provides the vessels with elasticity to physiologic 
demands as well as the ability to grow and develop new networks in response to 
regenerative signals. 
Angiogenesis, Vasculogenesis, Arteriogenesis. 
 In the developing embryo, blood vessels form through a process called 
vasculogenesis, in which the endothelial precursor angioblasts differentiate into 
endothelial cells, which then assemble in situ to form connected networks [241]. 
Postnatal vascular growth, however, occurs primarily through two mechanisms: 
arteriogenesis and angiogenesis [240]. Arteriogenesis features growth and dilation of 
existing arterioles by proliferation of endothelial and smooth muscle cells in response to 
demands for increased blood flow [240]. This mechanism is responsible for collateral 
vessel formation from pre-existing vessels and is thought to be the most rapid method for 
re-establishing blood supply in intact tissues [242]. However, arteriogenesis is incapable 
of establishing perfusion of newly-developed tissues, which requires a process of new 
blood vessel formation termed angiogenesis. Angiogenesis is defined as the sprouting of 
new capillaries from existing blood vessels and is triggered by hypoxia, resulting in 
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upregulation of the hypoxia-inducible factor-1 pathway, an upstream regulator of the 
potent angiogenic protein, VEGF, and matrix remodeling to allow for sprouting of 
nascent vessels and/or division of existing vessels [240].  
VASCULATURE, BONE AND MECHANICAL LOADING 
Bone is a highly vascularized tissue, and angiogenesis is essential to skeletal 
development [243-245]. Mature bone viability and healing are also fundamentally 
dependent on the vascular supply [15, 246]. Superior bone healing therefore requires both 
an optimal mechanical environment and a sufficient blood supply, and indeed, one of the 
primary limiting factors in successful bone defect healing is achieving sufficient vascular 
perfusion [15-16]. 
In long bone fracture healing, fixation stiffness regulates the canonical healing 
patterns, with interfragmentary motions caused by non-rigid fixation stimulating 
endochondral ossification and rigid fixation leading to intramembranous ossification [1, 
105-106, 116]. Likewise, the timing of vascular ingrowth is also known to alter healing 
patterns, as early vascularization is associated with intramembranous ossification and 
delayed ingrowth with endochondral ossification. Interfragmentary strains have been 
implicated as the driving force behind these tissue differentiation paradigms as a result of 
the homeostatic cellular response to maintain the capacity of the callus tissues to 
withstand the applied loads [247]. However, another potential rationale is that large 
interfragmentary strains disrupt microvessel formation leading to an avascular 
cartilaginous callus. This stiffening reduces interfragmentary motion, allowing initiation 
of vascular ingrowth and subsequent endochondral bone formation. Regardless of 
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pathway, sufficient vascularization is essential for timely healing, and insufficient 
vascular ingrowth can lead to delayed healing or even atrophic nonunion [159, 248-249]. 
Several ovine studies have indicated that altering the local mechanical 
environment results in modified vascular ingrowth and consequent fracture healing, 
though the window of therapeutic effect remains elusive. Wallace and colleagues found 
increased cortical and medullary blood flow as a result of decreased fixation stiffness 
[250], while Claes and co-workers showed decreased vascular ingrowth and increased 
fibrocartilage for increased interfragmentary strains [117]. Likewise, Lienau and 
colleagues demonstrated differential vessel formation and angiogenic gene expression in 
response to decreased fixation stability [149, 251]. 
While critically-sized segmental bone defect repair may not follow the same 
canonical patterns found in fracture healing, vascularization may play an even more 
critical role given the larger size of the defect. Mechanical stimulation remains a potent 
regulator of angiogenesis which may enhance vascularized bone defect repair by 
influencing tissue differentiation, vascular network formation, and subsequent mineral 
deposition. This thesis therefore investigated the ability of mechanical loading to regulate 
bone formation and vascular growth in tissue-engineered bone defect repair. 
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CHAPTER III: EFFECTS OF PROTEIN DOSE AND 





 Delivery of recombinant proteins is a proven therapeutic strategy to promote 
endogenous repair mechanisms and tissue regeneration. Bone morphogenetic protein-2 
(rhBMP-2) has been used to promote spinal fusion and repair of challenging bone 
defects; however, the current clinically-used carrier, absorbable collagen sponge, requires 
high doses and has been associated with adverse complications. We evaluated the 
hypothesis that the relationship between protein dose and regenerative efficacy depends 
on delivery system. First, we determined the dose-response relationship for rhBMP-2 
delivered to 8-mm rat bone defects in a hybrid nanofiber mesh/alginate delivery system at 
six doses ranging from 0 to 5 µg rhBMP-2. Next, we directly compared the hybrid 
delivery system to the collagen sponge at 0.1 and 1.0 µg. Finally, we compared the in 
vivo protein release profiles of the two delivery methods. In the hybrid delivery system, 
bone volume, connectivity and mechanical properties increased in a dose-dependent 
manner to rhBMP-2. Consistent bridging of the defect was observed for doses of 1.0 µg 
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and greater. Compared to collagen sponge delivery at the same 1.0 µg dose, the hybrid 
system yielded greater connectivity by week 4 and 2.5-fold greater bone volume by week 
12. These differences may be explained by the significantly greater protein retention in 
the hybrid system compared to collagen sponge. This study demonstrates a clear dose-
dependent effect of rhBMP-2 delivered using a hybrid nanofiber mesh/alginate delivery 
system. Furthermore, the effective dose was found to vary with delivery system, 
demonstrating the importance of biomaterial carrier properties in the delivery of 
recombinant proteins.  
 
INTRODUCTION 
  Large bone defects associated with high-energy trauma, fracture nonunion, and 
bone tumor resection present a difficult challenge to orthopaedic surgeons accentuated by 
the limited effectiveness of current treatment options. The gold standard of care, the 
autograft, in which bone graft particles are surgically transplanted from the patient‟s iliac 
crest, is limited by the available volume of graft material and significant donor site 
morbidity [9, 252]. Allografts are therefore often used to bridge the defects; however, 
these frequently fail to revascularize and remodel, resulting in graft fracture or tissue 
necrosis, requiring debridement and retreatment [10, 152, 253]. 
 Biomaterials-mediated delivery of biologic agents including growth factors, stem 
cells, and genes has been used to stimulate regeneration of the structure and function of 
various tissues and has specifically emerged as a promising alternative to bone grafting 
techniques [254]. Delivery of recombinant proteins is a particularly attractive therapeutic 
strategy to promote endogenous repair mechanisms and tissue regeneration [254]. For a 
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given protein, the delivery system may affect regenerative response by modulating 
protein stability and release kinetics. Langer and Folkman first demonstrated in 1976 the 
possibility of sustaining protein release via encapsulation in biocompatible polymers 
[255]. Since then, investigators have explored numerous materials and encapsulation and 
tethering techniques for tissue regenerative applications. For example, Griffith and 
colleagues have tethered growth factors to biomaterial substrates to regulate 
spatiotemporal presentation to mesenchymal stem cells and hepatocytes [219-221], and 
Phelps et al. covalently linked PEG hydrogels with vascular endothelial growth factor 
(VEGF) and cell adhesive peptides to enhance vascular network formation in vivo [222]. 
Others, such as Stayton and Mooney, have focused on modifying the degradation 
properties of various hydrogels to modulate growth factor delivery [223-224]. These 
inexhaustive examples illustrate the variety and power of the biomaterial delivery 
approach; however, degradation properties, release kinetics, and other material properties 
must be designed and tailored for each application [165, 225].  
 Delivery of recombinant human osteoinductive growth factors is one of the most 
successful and clinically-applicable bone tissue engineering strategies to date [165]. The 
principle of bone induction dates back to Marshal Urist‟s seminal discovery in 1965 of 
the potential of devitalized, decalcified allografts to induce heterotopic bone formation 
[99]. Subsequently, Urist, Reddi, and others extracted and identified the active biological 
agents, the bone morphogenetic proteins (BMPs), which belong to the transforming 
growth factor-β (TGF-β) supergene family [167, 171, 256-259]. Identification of the 
genetic sequence of BMP-2 by Wozney and colleagues enabled production of highly 
purified BMPs through recombinant gene technology, which has facilitated its use as a 
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clinical therapy [8, 157, 166, 171]. To date, two of the BMPs have been approved by the 
FDA for use in humans: BMP-2 and BMP-7, also known as human osteogenic protein-1 
(hOP-1) [182]. 
Portending the tissue engineering paradigm in the early 1980‟s, Reddi and 
colleagues first isolated and combined these soluble osteoinductive factors with insoluble 
substrata to induce bone formation [256-257]. This approach has seen continued success 
and aims to stimulate the endogenous regenerative potential of the host by recapitulating 
the molecular cascades that lead to bone formation during development [260-261]. 
However, as animal model and clinical data accumulate, the importance of the 
biomaterial carrier has become increasingly evident [173, 182], and while hOP-1 and 
rhBMP-2 have been successfully used in spinal fusion and open tibial fractures [262-
266], significant limitations to current delivery systems remain [173]. In current clinical 
practice, rhBMP-2 is delivered by implanting an absorbable collagen sponge soaked in 
water-solubilized protein [173]. However, complications associated with rapid protein 
degradation and diffusion (such as soft tissue inflammation and ectopic bone formation) 
[267-269], the cost of the high doses required for efficacy [183, 270-273], and concerns 
over a correlation between extremely high doses of rhBMP-2 and cancer incidence [274] 
suggest that spatiotemporal delivery strategies may improve the efficacy, efficiency, and 
safety of recombinant growth factor delivery.  
Of particular importance for growth factor delivery vehicles is the release profile 
of the protein from the scaffold, which must maintain a sufficient concentration to induce 
the desired response for a long enough time to promote recruitment of endogenous 
progenitor cells [165]. Development and assessment of such delivery vehicles requires 
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systematic evaluation of protein dose-response relationships as well as comparison to the 
current clinical standard for both protein release and function. Such studies will facilitate 
comparison between different carrier systems, animal models, and associated protein 
doses. 
 The goal of this study was therefore to characterize and evaluate the dose-
response of rhBMP-2 in a recently described protein delivery system designed to provide 
controlled spatial and temporal protein delivery [14], to compare this system with the 
clinically-used collagen sponge, and to explain the differences in response by quantifying 
the in vivo protein release profile of each. We hypothesized that bone regeneration 
responds in a dose-dependent manner to recombinant rhBMP-2 delivery in the nanofiber 
mesh/alginate delivery system and that this delivery system enhances bone regeneration 
over the currently used collagen sponge delivery method due to sustained protein release, 
thereby reducing the necessary effective dose. 
 
MATERIALS AND METHODS 
Surgical Procedure 
 Bilateral, critically-sized (8 mm) segmental defects were surgically created in 
femora of 13 week-old SASCO Sprague Dawley rats, as previously described [14, 275-
276]. Limbs were stabilized by custom radiolucent fixation plates that allowed in vivo 
monitoring with X-ray and microcomputed tomography (microCT). The experimental 
design featured 8 groups (Table 1, n = 9-10 per group). In 6 groups, the dose response of 
bone regeneration to rhBMP-2, when delivered in an alginate hydrogel, was evaluated at 
0.0, 0.1, 0.5, 1.0, 2.5, and 5.0 µg rhBMP-2, respectively. In these groups, a nanofiber 
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mesh tube was fitted over the bone ends, and RGD-functionalized alginate hydrogel 
[224] containing rhBMP-2 was injected into the defect space,
 
as described previously 
[14].  In the remaining 2 groups, 0.1 and 1.0 µg soluble rhBMP-2 was adsorbed onto an 8 
mm x 5 mm diameter collagen sponge, which was then press-fit into the defect. Post-
surgery, animals were given subcutaneous injections of buprenorphine every 8 hours for 
three days. All procedures were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee (IACUC, protocol # A08032). 
 
Table 3.1. Groups, analysis methods, and sample sizes. 
Groups Analysis Methods & Sample Sizes 
Dose  





0.0 Mesh/Alginate 10 10 9 1  - 
0.1 Mesh/Alginate 10 10 9 1  - 
0.5 Mesh/Alginate 10 10 9 1  - 
1.0 Mesh/Alginate 9 9 8 1  - 
2.5 Mesh/Alginate 10 10 9 1 6 
5.0 Mesh/Alginate 10 10 9 1  - 
0.1 Collagen Sponge 9 9 8 1  - 
1.0 Collagen Sponge 10 10 9 1  - 
2.5 Collagen Sponge - - - - 6 
 
Nanofiber Mesh Production 
 Nanofiber meshes were produced as previously described [14]. Briefly, poly-(ε-
caprolactone) (PCL) was dissolved at a concentration of 12% (w/v) in a 90:10 volume 
ratio of hexaflouro-2-propanol:dimethylformamide (Sigma-Aldrich) and electrospun onto 
a static collector. Twenty-four 1-mm diameter perforations were patterned into the 
nanofiber mesh sheets, which were then glued into tubes of 4.5 mm diameter and 12 mm 
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length. Mesh tubes were sterilized by 100% ethanol evaporation, and were stored in 
sterile phosphate buffered saline (PBS) prior to implantation. 
Alginate Gel & Collagen Sponge Growth Factor Loading 
 Recombinant human BMP-2 (R&D Systems) was reconstituted in 0.1% rat serum 
albumin in 4 mM HCl, according to manufacturer instructions. For the mesh/alginate 
delivery groups, the BMP-2 was then mixed at 6 different concentrations with RGD-
functionalized alginate [224, 277] to a final concentration of 2% alginate, which was 
cross-linked by mixing rapidly with 0.84% (m/v) CaSO4. The alginate hydrogel was 
covalently coupled with G4RGDASSP peptide sequences at 2 sequences per polymer 
chain using carbodiimide chemistry. Each defect received 200 µl of the pre-gelled 
alginate containing 0.0, 0.1, 0.5, 1.0, 2.5, or 5.0 µg rhBMP-2, depending on group. For 
the collagen sponge delivery groups, rhBMP-2 was pipetted onto the scaffolds 10 
minutes prior to implantation at either 2 or 20 µg/ml, for the 0.1 and 1.0 µg groups, 
respectively.  
Faxitron and MicroCT 
 Digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray Corp.) were taken at 
2, 4, 8, and 12 weeks post-surgery with an exposure time of 15 s and a voltage of 25 kV 
(n=10 per group). Bridging was defined by appearance of continuous bone crossing the 
defect. Bridging rates were blindly assessed by two independent observers, with 
differences determined by a third independent arbiter. At weeks 4, 8, and 12 post-surgery, 
animals were scanned using in vivo microCT (Viva-CT 40; Scanco Medical) at medium 
resolution and 38.5 µm isometric voxel size, with the scanner set at a voltage of 55 kVp 
and a current of 109 µA. The volume of interest (VOI) encompassed all bone formation 
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within the center 120 slices (4.56 mm) between the native bone ends. New bone 
formation was segmented by application of a global threshold (386 mg 
hydroxylapatite/cm
3
) corresponding to 50% of the native cortical bone density, and a 
Gaussian filter (sigma = 1.2, support = 1) was used to suppress noise. 
Biomechanical Testing 
 After 12 weeks, animals were euthanized by CO2 asphyxiation, and femora (n = 
8-9 per group) were excised for biomechanical testing in torsion to failure as described 
previously [275]. Briefly, limbs were cleaned of soft tissues and the ends potted in 
Wood‟s metal (Alfa Aesar). The fixation plates were then removed, and limbs were 
mounted on a Bose ElectroForce system (ELF 3200, Bose EnduraTEC) and tested to 
failure at a rate of 3º/sec. Maximum torque at failure and torsional stiffness, given by the 
slope of the line fitted to the linear region of the torque-rotation curve, were computed for 
each sample. 
Histology  
 One representative sample per group was taken for histology at week 12 post-
surgery. Samples were chosen based on microCT-calculated average bone volume at 
week 8. Samples were fixed in 10% neutral buffered formalin for 48 hours at 4ºC and 
then transferred to a formic acid-based decalcifier (Cal-ExII, Fisher Scientific) for 2 
weeks under mild agitation on a rocker plate. Following paraffin processing, 5 µm-thick 
mid-saggital sections were cut and stained with Safranin-O/Fast-green [278] and 
Haematoxylin and Eosin (H&E). Due to the presence of carboxyl groups, alginate carries 




 A separate study was conducted to compare the protein release and degradation 
over time in vivo. Segmental defects were created as described above and were treated 
with 2.5 µg near-infrared (NIR) fluorophore-tagged rhBMP-2, delivered in either 
collagen sponge or nanofiber mesh/alginate. rhBMP-2 was tagged with an in vivo NIR 
fluorochrome label (VivoTag-S 750, VisEn Medical) using NHS-ester chemistry. Briefly, 
rhBMP-2 was reconstituted in 4 mM HCl at a concentration of 100 µg/ml. Due to 
presence of glycine in the lyophilization buffer, the buffer was exchanged to 100 mM 
NaPO4 at pH 7.5 by two rounds of filtration through a 3 kDa centrifugal filter (Millipore 
Amicon Ultra, Millipore). The protein was then labeled by 4 hour incubation with 6 M 
excess of the fluorophore at room temperature. Excess fluorophore was removed by gel 
filtration through Zeba Spin Desalting Columns (7K MWCO, Fisher Scientific). Protein 
tagging was verified by SDS-PAGE. Labeled protein fluorescence was tracked over 21 
days in vivo using a 700 series Xenogen IVIS Imaging System. Animals were imaged at 
745 nm excitation, 780 nm emission and 60 s exposure time at 0, 3, 7, 14, and 21 days 
post-surgery. Fluorescence intensity was measured as background-subtracted average 
efficiency within a fixed region of interest (ROI) centered on the defect site. Values from 
each sample were normalized to that sample‟s initial intensity to represent percentage of 
protein remaining [225, 280]. Nonlinear regression analysis of release profiles were 
performed on raw data in GraphPad Prism using a one-phase exponential decay model 
(GraphPad Software, Inc.).  
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Statistical Analyses  
 All data are presented as mean ± standard error of the mean (SEM). Differences 
between groups and among time points were assessed by analysis of variance (ANOVA) 
with pairwise comparisons made by Tukey‟s post hoc analysis, Chi-squared analysis with 
individual comparisons made by Fisher‟s Exact test, analysis of covariance (ANCOVA) 
and Student‟s t-test, where appropriate (α = 0.05). A natural log transformation was 
applied to maintain normality of residuals and homogeneity of variance, when necessary 
and appropriate. Minitab® 15 (Minitab, Inc.) was used to perform the statistical analysis. 
 
RESULTS: DOSE-DEPENDENCY 
 First, the dose response of rhBMP-2 in the nanofiber mesh/alginate delivery 
system was evaluated over 12 weeks in critically-sized rat femoral bone defects. 
Faxitron 
 In vivo digital radiographs (Figure 3.1) qualitatively demonstrated a dose-
dependent bone formation response to rhBMP-2, and longitudinal evaluation of bridging 
rates likewise revealed significant dose-dependency of defect bridging to amount of 
delivered rhBMP-2 (Table 3.2). Groups with 1.0 µg rhBMP-2 or greater achieved 
consistent (80-100%) bridging by week 12 post-surgery. Doses less than or equal to 0.5 




Figure 3.1. Representative digital radiographs of segmental defects treated with 0.0, 0.1, 
0.5, 1.0, 2.5, and 5.0 µg rhBMP-2, as indicated, delivered in the nanofiber mesh/alginate 




Table 3.2. Defect bridging results vs. rhBMP-2 dose delivered in the mesh/alginate 
system. a: p < 0.05 vs. 0.0 µg group, b: p < 0.05 vs. 0.1 µg group, c: p < 0.05 vs. 0.5 µg 
group. 
Dose Week 2 Week 4 Week 8 Week 12 
0.0 µg 0/10 0/10 1/10 1/10 
0.1 µg 0/10 0/10 1/10 3/10 
0.5 µg 0/10 0/10 4/10 5/10 
1.0 µg 1/9 6/9 a, b, c 8/9 a, b 9/9 a, b, c 
2.5 µg 2/10 6/10 a, b, c 8/10 a 8/10 a 
5.0 µg 3/10 9/10 a, b, c 10/10 a, b, c 10/10 a, b, c 
 
Microcomputed Tomography 
 MicroCT scans confirmed the two-dimensional X-ray results. Minimal bone 
formation occurred at low doses. Beginning at the 0.5 µg dose, however, bone formation 
was evident at the center of the defects as well as on the surfaces of the nanofiber mesh, 
where the holes in the newly formed bone corresponded with mesh perforations (Figure 
3.2). Local density maps on saggital cross sections demonstrated the distribution and 
maturity of bone within the defects (Figure 3.2). At doses larger than 1.0 µg, bone formed 






Figure 3.2. MicroCT reconstructions showing 3D structure and saggital cross sections 
illustrating local mineral density mapping. Segmental defects were treated with 0.0, 0.1, 
0.5, 1.0, 2.5, and 5.0 µg rhBMP-2, as indicated, delivered in the nanofiber mesh/alginate 
delivery system.  
 
 MicroCT was used to quantify 3D tissue ingrowth parameters including volume, 
density, and connectivity of the newly formed bone. In the mesh/alginate groups, bone 
formation responded in a nonlinear, dose-dependent manner to rhBMP-2. By week 12, 
the 1.0 and 2.5 µg doses had significantly greater bone volume than 0.0, 0.1, and 0.5 µg 
doses, and the 5.0 µg dose group exhibited significantly greater bone volume than all 
other groups (Figure 3.3A). The dose-response curve exhibited linear biphasic behavior, 
with the slope (m_bv) of the bone volume vs. dose curve decreasing significantly (p < 
0.0001) at 1.0 µg or greater (m_bv0.0-1.0 = 50.1 ± 4.8 mm
3





= 0.75 and 0.30, respectively, at week 12). Connectivity increased with 
rhBMP-2 dose in a similar manner to bone volume. However, unlike bone volume, the 
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connectivity of the bone microstructure decreased with time as the initial finely-
trabeculated structure was remodeled between 4 and 12 weeks (Figure 3.3B). There were 
no differences in mean mineral density among the dose groups at any time point, though 






Figure 3.3. MicroCT quantification of bone volume, connectivity, and mean density as a 
function of rhBMP-2 dose at week 4 (light dashed lines), week 8 (bold dashed lines), and 
week 12 (solid lines). Bone volume (A) and connectivity (B) demonstrated nonlinear 
dose-dependent responses to rhBMP-2, with a reduction in response to increased dose 
above 1.0 µg. No differences between groups were found for mean density (C). a: p < 
0.05 as indicated, b: p < 0.05 vs. all other groups. 
 
Biomechanical Testing 
 To evaluate the degree of functional restoration, biomechanical testing in torsion 
to failure was performed on potted femurs. Biomechanical properties increased 
continuously with increasing dose of rhBMP-2, with the 1.0, 2.5, and 5.0 µg groups 
having significantly greater torsional stiffness (Figure 3.4A) and maximum torque at 




connectivity, which featured a reduction in response to increasing dose at doses greater 
than 1.0 µg rhBMP-2, mechanical properties exhibited continuously increasing stiffness 
and torque with increasing protein dose, and the dose-response curves did not 
significantly change slope over the range of doses evaluated (p = 0.47 and p = 0.65 for 
stiffness and torque, respectively).  
 
 
Figure 3.4. Post-mortem biomechanical properties as a function of rhBMP-2 dose. 
Torsional stiffness (A) and failure torque (B) continuously increased with increasing dose 
of rhBMP-2. a: p < 0.05 as indicated, b: p < 0.05 vs. all other groups. 
 
Histology 
 Histological staining allowed evaluation of tissue morphology, cellular 
infiltration, and alginate gel degradation at week 12. Haematoxylin and Eosin staining 
revealed a mixture of osteocyte-populated woven and lamellar bone in groups with bone 
formation (Figure 3.5A). In the 0.0 µg group, the defect space appeared highly 
homogeneous and filled with alginate gel. In this group, very few cells had migrated into 
the defect space, and tissue invasion into the alginate was minimal. In contrast, large 
numbers of invading cells were present in all other groups, even at very low doses of 




degree of fragmentation of the alginate gel was found through Safranin-O/fast green 
staining to likewise be dose-dependent, featuring negligible dissolution in the 0.0 µg 
group and increased tissue invasion and alginate fragmentation with increasing amounts 
of rhBMP-2 (Figure 3.5B). Regardless of protein dose, the gel did not completely 
degrade by 12 weeks, as indicated by the presence of small regions of alginate embedded 






Figure 3.5. Week 12 histological staining of saggital sections at each dose of BMP-2, 
delivered in the mesh/alginate delivery system. H&E staining (A) illustrated bone 
formation (white arrow) and cellular invasion. Images at 20x, scale bars: 50 µm. 
Safranin-O/fast green staining at 4x (B) illustrated dose-dependent increases in alginate 
gel (black arrow) fragmentation and degradation as well as tissue infiltration (fast green 




RESULTS: DELIVERY SYSTEM COMPARISON 
 Next, we compared the nanofiber mesh/alginate delivery system at a non-bridging 
dose (0.1 µg) and a bridging dose (1.0 µg) with the clinically-used collagen sponge 
delivery system at the same doses. Finally, we compared the in vivo protein release 
kinetics of the two delivery methods using fluorophore-tagged rhBMP-2.  
Faxitron 
 In vivo digital radiographs (Figure 3.6) qualitatively demonstrated a delivery 
system-dependent bone formation response to rhBMP-2. At 1.0 µg rhBMP-2, the 
mesh/alginate delivery system resulted in 100% defect bridging by week 12, while 
collagen sponge delivery resulted in 60% bridging, though this difference was not 
statistically significant with p = 0.0867 (Table 3.3). 0.1 µg rhBMP-2 was insufficient to 
induce robust bone formation in either delivery system. 
 
Figure 3.6. Representative digital radiographs of segmental defects treated with 0.1 or 








Table 3.3. Defect bridging results based on delivery system. d: p < 0.05 vs. collagen 0.1 
µg group. 
Group Week 2 Week 4 Week 8 Week 12 
M/A 0.1 µg 0/10 0/10 1/10 3/10 
Col 0.1 µg 0/9 0/9 0/9 0/9 
M/A 1.0 µg 1/9 6/9 8/9 9/9 
Col 1.0 µg 1/10 3/10 4/10 6/10 d 
 
Microcomputed Tomography 
 MicroCT scans again confirmed the two-dimensional X-ray results and clearly 
illustrated differences in delivery systems at 1.0 µg rhBMP-2 (Figure 3.7). Local density 
maps on saggital cross sections demonstrated the distribution and maturity of bone within 
the defects (Figure 3.7). Collagen groups exhibited formation of thin bony shells 
containing small amounts of trabeculated bone, while the mesh/alginate group featured 
bone formation throughout the defect at 1.0 µg. 
 
Figure 3.7. MicroCT reconstructions showing 3D structure and saggital cross sections 
with local mineral density mapping to illustrate bone formation, defect bridging and 
tissue maturity.  
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 Quantification of microCT images revealed significant differences in bone 
formation between the collagen sponge and mesh/alginate delivery systems (Figure 3.8A-
I). At week 4, there were no differences in bone volume between groups at either 0.1 or 
1.0 µg dose (Figure 3.8A). However, by week 8, the bone volume in the mesh/alginate 
1.0 µg group was significantly greater than the collagen sponge 1.0 µg group, and this 
effect widened to 2.5-fold greater by week 12 (Figure 3.8B, C). Temporally, bone volume 
increased significantly from week 4 to weeks 8 and 12 with mesh/alginate delivery, 
whereas with collagen sponge delivery, bone formation occurred rapidly over the first 4 
weeks but did not increase significantly after week 4. Connectivity was significantly 
greater in the mesh/alginate 1.0 µg group than the collagen sponge 1.0 µg group at both 
weeks 4 and 8 (Figure 3.8D, E); however, by week 12, the connectivity had normalized 
in both groups (Figure 3.8F). As among the mesh/alginate groups, no differences in mean 
mineral density were found between groups, though the density increased with time in 
each group (Figure 3.8G-I). No differences in bone formation were found between 





Figure 3.8. MicroCT quantification of bone volume (A-C), connectivity (D-E), and mean 
density (G-I) at week 4 (A, D, G), week 8 (B, E, H) and week 12 (C, F, I) post-surgery. 
Dark bars represent mesh/alginate delivery system and light bars represent collagen 
sponge delivery system. Mesh/alginate delivery yielded an early increase in connectivity 
(D) and conferred a 2.5-fold greater bone volume by week 12 (C) in comparison to 
collagen sponge delivery. Mean mineral density was not significantly dose- or delivery 
system-dependent. a: p < 0.05 as indicated, c: p < 0.05 vs. week 4, d: p < 0.05 vs. week 8. 
 
Biomechanical Testing 
 Differences in torsional stiffness and maximum torque did not reach significance 
between collagen and mesh/alginate delivery, p = 0.057 and p = 0.082, respectively, 
though dose-dependent differences were apparent as before (Figure 3.9A, B).  




Figure 3.9. Post-mortem biomechanical testing revealed significant dose-dependent 
increases in stiffness (A) and failure torque (B) but differences between delivery systems 
did not reach significance at either dose. a: p < 0.05 as indicated. 
 
Histology 
 Histological staining with Safranin-O was performed to compare tissue 
morphology and composition between delivery systems at week 12 (Figure 3.10). In 
contrast to the mesh/alginate groups which contained substantial amounts of non-
degraded hydrogel through week 12, the collagen sponges had completely resorbed. In 
the collagen sponge 0.1 µg group, defects were filled primarily with fibrous tissue, while 
in the collagen sponge 1.0 µg group, the new bone formed thin shells, containing 





Figure 3.10. Week 12 histological staining of saggital sections. H&E staining (A) 
illustrated bone (b) and fibrous tissue (f) formation and residual alginate (a). Images at 
20x, scale bars: 50 µm. Staining with Safranin-O (B) revealed a significant persistence of 
alginate gel (a) through week 12 in the mesh/alginate group. Large amounts of fibrous 
tissue (f) were apparent in the collagen sponge group at 0.1 µg, while at 1.0 µg small 
amounts of trabecular bone (b) and fatty marrow filled the defect. The collagen sponge 
had entirely absorbed by week 12 in both collagen sponge groups. Images at 4x, scale 





 To investigate a possible mechanism for the observed delivery system-dependent 
increases in bone formation, fluorescently-labeled protein was tracked over 3 weeks 
(Figure 3.11). For both delivery systems, the labeled protein profile decreased 
monotonically with time and >90% of the initial dose delivered was released by 21 days. 
The percentage of protein remaining in the defect region was significantly elevated in the 
mesh/alginate group compared to collagen sponge at both 3 and 7 days post-implantation. 
Based on a simple release model, the protein profiles were fit to an exponential decay to 
estimate the half-life of release (R
2
= 0.946 and 0.857 for collagen sponge and 
mesh/alginate groups, respectively). Overall, the half-life of release was 1.87 days (95% 
CI: 1.49 - 2.49 days) and 3.19 days (95% CI: 2.23 - 5.59 days) for the collagen sponge 
and mesh/alginate, respectively, though the difference did not reach statistical 
significance with p = 0.094. No significant differences in spatial distribution were found 





Figure 3.11. BMP release: in vivo tracking of fluorescent tag-labeled rhBMP-2 (inset) 
over 21 days revealed a significantly elevated protein retention in the mesh/alginate 
group compared to collagen sponge at day 3 and 7 post-implantation. Solid lines 
represent curve fit to exponential decay (R
2
 = 0.946 and 0.857 for collagen sponge and 
mesh/alginate groups, respectively). The half life of release was 1.87 days (95% CI: 1.49 
to 2.49 days) and 3.19 days (95% CI: 2.23 to 5.59 days), for the collagen sponge and 
mesh/alginate, respectively. *: p < 0.05 mesh/alginate vs. collagen sponge. 
 
 SDS-PAGE analysis verified that the tagged protein had similar molecular weight 
to the untagged protein (Figure 3.12). In vitro bioactivity assays and bone formation in 
vivo demonstrated that the tagged rhBMP-2 maintained biofunctionality, capable of 
inducing osteogenic differentiation of mesenchymal stem cells to a similar degree as un-
tagged protein, as measured by calcium deposition in vitro (Figure 3.13A), though tagged 
protein induced a lesser amount of bone formation in vivo suggesting a somewhat 




Figure 3.12. SDS-PAGE analysis of rhBMP-2 and fluorophore-tagged rhBMP-2 under 
reducing conditions. (A): SYPRO-Ruby protein gel stain illustrating untagged rhBMP-2 
and tagged rhBMP-2 at similar molecular weight. (B): fluorescence imaging further 
verified the presence of tagged protein with functional fluorophore. Both labeled and 










Figure 3.13. Labeled protein bioactivity analyses. (A): In vitro calcium deposition of 
MSCs after exposure to rhBMP-2 and fluorophore-tagged rhBMP-2. * indicates p < 0.05 
vs. both CM and CM + Dex. NS = not significant. (B): Faxitron images of bone 
formation under tagged bmp-2 vs. non-tagged rhBMP-2 at 2.5 µg. In vitro bioactivity 
assays and bone formation in vivo demonstrated that the tagged rhBMP-2 maintained 
biofunctionality, capable of inducing osteogenic differentiation of mesenchymal stem 
cells to a similar degree as un-tagged protein, though tagged protein induced a lesser 
amount of bone formation in vivo suggesting a somewhat reduced activity. 
 
DISCUSSION 
 Delivery of recombinant proteins carries great promise for the field of 
regenerative medicine; however, optimal doses and delivery vehicles have not yet been 
 
 60 
determined. This study presents the dose-response relationships for rhBMP-2 delivered in 
a controlled-release hydrogel in comparison to the currently-used collagen sponge carrier, 
and revealed a reduction in the necessary effective dose for the spatiotemporal delivery 
system.  
Dose-dependency 
 When delivered in the nanofiber mesh/alginate delivery system, rhBMP-2 induced 
bone regeneration in a nonlinear dose-dependent manner, as evaluated by bridging rate, 
bone volume, connectivity, and mechanical properties. Interestingly, the dose-response 
curves for bone volume and connectivity exhibited linear biphasic characteristics, with 
the slope significantly decreasing after the onset of bridging at 1.0 µg. This decrease in 
responsiveness to rhBMP-2 with increasing dose is likely due to saturation of BMP 
receptors and responding cell supply or simply from bone filling up available space in the 
defect region. Consistent with the onset of defect bridging, torsional stiffness and strength 
were not dose-responsive at less than 1.0 µg, but at higher doses, exhibited significant 
dose-dependent increases in mechanical properties. 
 The observation that mechanical properties did not level off within the range of 
growth factor dose analyzed may be explained by the histological observation that 
alginate degradation also proceeded in a dose-dependent manner, such that at higher 
doses, increased gel degradation allowed improved mechanical integrity. Since alginate is 
algae-derived, it cannot be enzymatically degraded in vivo, requiring hydrolysis or loss of 
the cross-linking Ca
2+
 ions for degradation [224]. The observed increase in cell and tissue 
infiltration with increasing dose may have increased the number of cells responsible for 
clearing foreign material and exposed more of the alginate surface for hydrolysis, 
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contributing to the dose-dependence of gel degradation. Another possible explanation is 
that the presence of the rhBMP-2 in the gel directly affected mechanical properties or 
degradation profiles independent of cellular and tissue interactions. Together, these 
effects allowed increased mechanical integrity in the higher doses which contained more 
bone and lower amounts of residual hydrogel.  
 For comparison, the mechanical properties of age-matched intact femurs were 
0.030 ± 0.001 N-m/deg and 0.31 ± 0.02 N-m for torsional stiffness and failure torque, 
respectively [276]. At the 5.0 µg dose, the torsional stiffness of the regenerated defects 
exceeded the intact bone stiffness, while the failure torque reached about 60% of that of 
the intact bone. A previous study using this model demonstrated similar results, with 
mesh/alginate delivery of 5 µg rhBMP-2 reaching about 75% of intact bone properties for 
both stiffness and torque, though these were not statistically different from the native 
bone properties [14]. 
 The nanofiber mesh tube, while serving to spatially retain the alginate and 
resulting bone formation within the defect, also appeared to be supportive of bone 
formation. Osteocyte-populated woven bone developed on the surfaces of the nanofiber 
meshes, in some cases creating sheets of bone which highlighted the presence of the 
mesh perforations. This observation was most clearly observed in the 0.5 µg group and, 
though present, was less noticeable in the higher dose groups as the defects were filled 
with bone. This suggests that rhBMP-2 was either binding to the nanofiber mesh and 
inducing bone formation locally, or perhaps more likely, the mesh was conducive to 
cellular migration and differentiation, allowing migration of periosteal cells along the 
mesh. This later possibility is corroborated by in vitro studies conducted in our laboratory 
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which demonstrated increased mesenchymal stem cell migration and osteogenic 
differentiation on nanofiber meshes compared with tissue culture plastic [281]. 
Delivery System Comparison 
 Bone formation was significantly increased in the nanofiber mesh/alginate 
delivery system over the current clinically-used collagen sponge delivery method for the 
1.0 µg groups. Although the amount of bone formation was similar at week 4, by week 8 
there was significantly greater bone volume in the mesh/alginate group compared to the 
collagen sponge group, and this difference increased through week 12. By week 4, the 
amount of active rhBMP-2 remaining in the defect would likely be minimal for both 
groups, however, this enhancement in bone formation between week 4 and week 8 in the 
mesh/alginate system may be attributed to an increased attraction of cells into the defect 
at earlier time points or enhanced activation of those cells from the released rhBMP-2, 
resulting in elevated activity through week 8. 0.1 µg rhBMP-2 was not sufficient to 
induce robust bone formation; however, 0.1 µg caused substantial increases in cellular 
migration into the defect compared to mesh/alginate-only treatment, demonstrating that 
even a low dose of rhBMP-2 possesses potent chemoattractant capacity for endogenous 
cells [282] and suggesting that low doses of rhBMP-2 may be useful for combination 
strategies involving gene therapy or growth factor co-delivery which require a strong host 
cell response. To facilitate cellular invasion, the alginate gel was functionalized with 
RGD peptides. RGD (Arg-Gly-Asp) is the primary sequence motif of fibronectin 
responsible for integrin binding, and may have enhanced protein-cell-matrix interactions 
and the ability of cells to migrate into the defect [224]. The RGD alone was not sufficient 
to induce cellular invasion or gel dissolution, as evident in the 0.0 µg group, though 
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cellular infiltration and associated gel fragmentation increased in an rhBMP-2 dose-
dependent manner.  
 Although early bone formation occurred at a similar rate between delivery 
systems, an early enhancement in connectivity was observed in the mesh/alginate group, 
and this difference persisted through week 8. In both delivery systems, however, the 
connectivity decreased with time, despite increasing with dose of rhBMP-2, resulting in 
similar connectivity at week 12. As connectivity is a normalized measure of the number 
of redundant structures, the dose-dependent increase may be explained by an increase in 
the number of bone nucleation sites. However, as time progressed, spaces between 
distinct islands of bone filled in, reducing the total number of unique structures within the 
defect space, causing a reduction in connectivity over time, though the actual integrity 
increased. 
 Differences in mechanical properties between the collagen and mesh/alginate 
systems did not reach statistical significance, though the trends were consistent with the 
observed differences in bone formation. As seen histologically, the alginate hydrogel did 
not fully degrade over the time course of the study, and the extant alginate gel may have 
interfered with the mechanical integrity of the resulting bone by preventing complete 
interconnectivity. This underscores the importance of optimizing carrier degradation 
kinetics and protein-carrier concentrations for effective sustained delivery. 
 To explain the differences in bone formation between the two delivery systems, 
we quantified the in vivo protein release profiles of each. Sustained delivery vehicles for 
recombinant proteins have been studied previously, primarily using 
125
I-labeled proteins 
[225, 280, 283-288]. In this study, the protein release kinetics from the collagen sponge 
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were similar to those reported previously in ectopic bone formation models, in which the 
retention half-life ranged from several hours to several days [289-292]. In comparison to 
collagen sponge, the sustained delivery method examined here increased the protein 
retention, and resulted in a 2.5-fold increase in bone volume over collagen sponge 
delivery.  
 A possible limitation of the protein tagging technique is that the fluorophore 
attachment may have altered the release properties of the protein. However, since the 
protein was not substantially changed in size as a result of complexation and did maintain 
bioactivity, albeit somewhat reduced in vivo compared to un-tagged protein, it is likely 
that the diffusion properties were not substantially changed. Regardless, both collagen 
sponge and mesh/alginate delivery systems were analyzed with the same tagged protein, 
allowing direct comparison. As with all protein labeling techniques, the entity being 
tracked is the fluorophore, with the degree of fluorophore-protein dissociation an 
unknown. Dissociation would result in measurement of faster release kinetics than 
actually exist as the fluorophore is substantially smaller in size than the fluorophore-
protein complex, resulting in greater diffusivity according to the Einstein-Stokes relation. 
However, in this experiment, both groups received the same labeled protein, processed 
identically, and the fluorophore-protein dissociation rate is not likely to differ between 
delivery systems. Together, these limitations accentuate the importance of including the 
collagen group when evaluating sustained delivery vehicles for recombinant proteins to 
provide direct comparison of the novel therapeutic with the clinical standard.  
 In this study, several combined factors may have prolonged the protein release in 
the mesh/alginate system. First, the alginate hydrogel mesh structure provides a 
 
 65 
diffusional barrier to BMP release, whereas the collagen sponge relies mostly on 
desorption. Second, the slow degradation kinetics of the alginate gel, despite inhibiting 
whole bone remodeling, may have contributed to the slower release kinetics. Third, the 
presence of the nanofiber mesh tube has been shown to maintain spatial retention of 
alginate in the defect [14] and may contribute to protein retention as well. Finally, since 
alginate carries a negative charge [293], and rhBMP-2 carries a positive charge of 10.5 at 
pH 7.4 [294], the opposite protein-matrix charge interactions may also have contributed 
to protein retention. Specifically, alginate has been shown to reversibly bind to heparin-
binding proteins such as BMP-2 due to the abundance of basic residues in the heparin 
binding sequence, promoting interaction with negatively charged carboxyl groups on the 
alginate chain [295-296]. This interaction has been shown to enhance the biological 
activity of these proteins, likely through protection from degradation [286]. 
 Much attention has recently been placed on developing improved carriers for both 
rhBMP-2 and hOP-1 [225, 297-298]. Likewise, the kinetics of protein release have been 
shown to have profound effects on protein effectiveness and efficiency [225, 280]. For 
example, Li et al. evaluated the bone formation capacity of rhBMP-2 when delivered in 
polyurethane scaffolds possessing different release kinetics, and found improved healing 
in scaffolds featuring an initial burst followed by sustained release [299]. Subsequently, 
Brown et al. demonstrated that a burst followed by a sustained release of rhBMP-2 
regenerated 50% more bone compared to collagen sponge [300]. These results suggest 
that some amount of early release combined with sustained delivery may enhance growth 
factor efficacy, and together with the present data emphasize the importance of 




 These data demonstrate the dose-response and temporal release of rhBMP-2 in a 
spatiotemporal protein delivery system, in comparison to the clinical standard collagen 
sponge. This work demonstrates an improvement in bone formation over current rhBMP-
2 delivery methods, and highlights the importance of quantification of release kinetics 
and scaffold degradation properties for evaluating novel recombinant protein carriers. 
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CHAPTER IV: EFFECTS OF IN VIVO MECHANICAL LOADING 




Fracture healing is highly sensitive to mechanical conditions; however, the effects 
of mechanical loading on large bone defect regeneration have not been evaluated. In this 
study, we investigated the effects of functional loading on repair of critically sized 
segmental bone defects. Six-mm defects were created in rat femora, and each defect 
received 5 µg recombinant human bone morphogenetic protein-2 (rhBMP-2), delivered in 
alginate hydrogel. Limbs were stabilized by either stiff fixation plates for the duration of 
the study or compliant plates that allowed transfer of compressive ambulatory loads 
beginning at week 4. Healing was assessed by digital radiography, microcomputed 
tomography, mechanical testing, histology, and finite element modeling. Loading 
significantly increased regenerate bone volume and average polar moment of inertia. The 
response to loading was location-dependent with the polar moment of inertia increased at 
the proximal end of the defect but not the distal end. As a result, torsional stiffness was 
58% higher in the compliant plate group, but failure torque was not altered. In the limited 
number of samples assessed for histology, a qualitatively greater amount of cartilage and 
a lesser degree of remodeling to lamellar bone occurred in the loaded group compared to 
the stiff plate group. Finally, principal strain histograms, calculated by FE modeling, 








revealed that the compliant plate samples had adapted to more efficiently distribute loads 
in the defects. Together, these data demonstrate that functional transfer of axial loads 
alters BMP-induced large bone defect repair by increasing the amount and distribution of 
bone formed within the defect.  
 
INTRODUCTION 
Bone uniquely adapts and remodels its architecture and properties to respond to 
its mechanical environment, and mechanical forces are essential for proper 
morphogenesis and maintenance of normal bone structure and function [301]. Bone 
repair is also acutely responsive to loading, and both fracture healing and distraction 
osteogenesis are highly sensitive to mechanical stimuli, with the local mechanical 
environment being a primary determinant of the course and success of healing [1-2]. 
 The benefits of mechanical stimulation in bone repair have only recently been 
recognized, as it was long held that complete immobilization was imperative for 
successful fracture healing and that the resorptive effect of disuse was necessary to 
release calcium for callus mineralization [302]. However, the continued study of 
biomechanical factors in fracture healing has drastically changed the way that fractures 
are clinically addressed [106-107, 111]. It is now known that limited compressive 
interfragmentary movements induce endochondral ossification and have a stimulatory 
effect on callus formation and subsequent healing [1, 105, 109, 114].  
Although biomechanical modulation of fracture healing has been well studied, the 
ability of mechanical stimulation to enhance large bone defect repair has not yet been 
quantitatively evaluated. Large bone defects, caused by traumatic injury, tumor resection, 
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or degenerative disease, remain a significant challenge for orthopaedic surgeons, as the 
current treatment options are limited by tissue availability and donor site morbidity, in the 
case of autografts, and failure to revitalize and remodel, in the case of allografts [9-10, 
152]. Tissue engineering, the use of biomaterial scaffolds in combination with biologics 
and/or cells, has therefore emerged as a promising alternative to grafting techniques. One 
tissue engineering strategy that shows immense potential is the delivery of recombinant 
osteoinductive growth factors, such as members of the bone morphogenetic protein 
(BMP) family. Two of these, BMP-2 and BMP-7, have been approved for use in humans 
by the United States Food and Drug Administration (FDA), and have shown great 
promise in numerous animal models and clinical trials [182, 303-304]. The clinical 
delivery method for these proteins, however, may be inefficient as large doses are 
required, contributing to prohibitively-high costs and potential complications due to 
protein diffusion [182, 303]. A recently-developed growth factor delivery system, using 
an alginate hydrogel injected into a nanofiber mesh tube placed around the defect, has 
been shown to enhance functional repair of bone defects [305]. Such advances are 
increasing the potential to safely and effectively restore bone function in challenging 
segmental defects.  
However, few studies have directly investigated the influence of mechanical 
conditions in tissue-engineered bone repair. While a number of laboratories have 
explored mechanical deformations of bone cells and tissue-engineered constructs in vitro 
[11, 232, 236, 238-239], very few have studied these in vivo [13, 306-307], and the 
potential of mechanical loading to enhance the regeneration of large bone defects has not 
been evaluated. This approach has the potential to improve clinical treatment of such 
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challenging defects as well as advance our understanding of the role of mechanical 
factors in bone tissue formation, differentiation, and remodeling. The aim of this study 
was therefore to test the hypothesis that transfer of compressive ambulatory loads during 
segmental bone repair enhances bone formation and subsequent regeneration.  
 
MATERIALS AND METHODS 
Surgical Procedure 
Bilateral 6 mm femoral defects were surgically created in 13 week old female 
SASCO Sprague Dawley rats (Charles River Labs, Wilmington, MA) under isoflurane 
anesthesia as previously described [275]. Limbs were stabilized by either stiff or axially-
compliant fixation plates as characterized previously [276] (n = 10 per group, Figure 
4.1A-C). The compliant plates maintained a high stiffness to bending and torsional loads, 
but allowed transfer of compressive ambulatory loads through integrated elastomer 
segments (RTV Silicone Adhesive, Factor II, Inc., Lakeside, AZ) that conferred a low 
axial stiffness [276]. The compliant plates also featured a locking mechanism to allow 
elective actuation of load-sharing after an initial healing period, selected to be 4 weeks in 
the current study. The axial, torsional, and bending properties of the plates in each 
configuration are shown in Table 4.1. In the locked configuration, the compliant plates 
featured an axial stiffness of 349.5 ± 35.1 N/mm, which was reduced to 8.4 ± 0.4 N/mm 
by plate actuation. By comparison, the stiff plates featured an axial stiffness of 214.3 ± 




Figure 4.1. Fixation plate designs. (A): Stiff plate. (B): Locked compliant plate. (C): 
Actuated compliant plate.  
 
Table 4.1. Fixation plate mechanical characterization. All values given as mean ± 
standard deviation.  
  Stiff Plate 
Compliant Plate  
Actuated Locked 
Axial Stiffness (k) 
without scaffold 
[N/mm] 
214.3 ± 4.1 8.4 ± 0.4 349.5 ± 35.1  
Axial Stiffness (k) 
with scaffold 
[N/mm] 




14.8 ± 1.61 6.95 ± 0.18 9.14 ± 2.94 
Flexural Rigidity 
(EI) concave     [N-
mm^2] 
29236.3 ± 260.8 25688.3 ± 657.4  26938.7 ± 629.5  
Flexural Rigidity 
(EI) convex      [N-
mm^2] 
30472.0 ± 736.8 28015.0 ± 2076.1 42392.0 ± 8350.1  
 
Preliminary experiments (not shown) suggested that without defect bridging, 
mechanical loading may not have a beneficial effect. Therefore, in this experiment, 6 mm 
defects were used to ensure bridging of the defects at the onset of mechanical loading at 
week 4. An initial pilot study verified that these defects were critically sized, and bony 






Figure 4.2. Week 12 histological staining: Haematoxylin and Eosin-stained sections of 
empty (A) and nanofiber mesh-only treated (B) defects at week 12 post-surgery. In the 
absence of rhBMP-2, the defects filled with fibrous tissue and resulted in non-union. 
Histological assessment demonstrated that in both groups, the defect ends were capped 
off by new bone (red), with muscle and fibrous tissue invasion (pink) into the defect from 
the periphery in the empty group and fibrous tissue and regions of empty space in the 
nanofiber mesh-only group. Limbs failed to bridge without treatment, confirming the 
critical nature of the model. 
 
After limb stabilization, a nanofiber mesh tube was inserted over the native bone 
ends, surrounding the defect as described in Chapter 1. 100 µl of alginate hydrogel, 
containing 5 µg of BMP-2, was then injected into each mesh using a blunt-tipped 22g 
needle, filling the defect space.  
Animals were given subcutaneous injections of 0.04 mg/kg buprenorphine every 
8 h for the first 48 h post-surgery and 0.013 mg/kg every 8 h for the following 24 h. All 
procedures were reviewed and approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee (Protocol No. A08032). 
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Nanofiber Mesh Production 
Nanofiber meshes were produced as described previously by electrospinning 
poly-(ε-caprolactone) (PCL) onto a static collector [308]. Briefly, PCL was dissolved at a 
concentration of 12% (w/v) in a 90:10 volume ratio of hexaflouro-2-
propanol:dimethylformamide (Sigma-Aldrich) and electrospun onto a collector. Twenty-
four 1 mm diameter perforations were patterned into the sheets, which were then glued 
into tubes of 4.5 mm diameter and 10 mm length. Mesh tubes were sterilized by 100% 
ethanol evaporation. 
Alginate & Growth Factor Loading 
Recombinant human BMP-2 (R&D Systems, Minneapolis, MN) was reconstituted 
in 0.1% rat serum albumin in 4mM HCl, and mixed with RGD-functionalized alginate 
(courtesy of David Mooney, Harvard University) [277] to a final concentration of 50 
µg/ml in 2% alginate. To crosslink the alginate, this solution was mixed rapidly with 
0.84% (m/v) CaSO4. Each defect received a total of 5 µg BMP-2. 
Faxitron and MicroCT 
Two-dimensional digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray 
Corp., Wheeling, IL) were taken at 2, 4, 8, and 12 weeks post-surgery with an exposure 
time of 15 s and a voltage of 25 kV (n=10 per group). In vivo micro-computed 
tomography (microCT) scans (Viva-CT 40; Scanco Medical, Basserdorf, Switzerland) 
were performed at 4, 8, and 12 weeks post-surgery at medium resolution and 38.5 µm 
isometric voxel size with the scanner set at a voltage of 55 kVp and a current of 109 µA. 
The volume of interest (VOI) used for quantification of bone volume and bone density 
encompassed all bone formation within the center 100 slices (3.85 mm) between the 
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native bone ends. New bone formation was segmented by application of a global 
threshold (386 mg hydroxylapatite/cm
3
) corresponding to 50% of the native cortical bone 
density, and a Gaussian filter (sigma = 1.2, support = 1) was used to suppress noise.  
After 12 weeks (8 weeks after compliant plate actuation), the animals were 
euthanized by CO2 asphyxiation, and the limbs were excised for microCT scanning to 
quantify bone distribution (n=8 per group). Ex vivo scans were performed as above at 
medium resolution with a 21 μm voxel size. The ex vivo VOI included the defect plus 2 
mm of native bone on each end, to encompass the entire region exposed to a torsional 
moment during mechanical testing. To assess the cross-sectional bone distribution, the 
“Bone Midshaft” evaluation script (Scanco Medical, Basserdorf, Switzerland) was used 
to quantify polar moment of inertia (pMOI). 
Biomechanical Testing 
Femora (n=8 per group) were then biomechanically tested in torsion to failure as 
described previously [275]. Briefly, limbs were cleaned of soft tissues and the ends 
potted in Wood‟s metal (Alfa Aesar, Wood Hill, MA). The fixation plates were then 
removed, and limbs were mounted on a Bose ElectroForce system (ELF 3200, Bose 
EnduraTEC, Minnetonka, MN) and tested to failure at a rate of 3º/sec. Maximum torque 
at failure and torsional stiffness, given by the slope of the line fitted to the linear region of 
the torque-rotation curve, were computed for each sample. 
Histology 
One sample per group was taken for histology at week 5 (one week after 
compliant plate actuation) and at week 12 post-surgery. Samples were fixed in 10% 
neutral buffered formalin for 24 hours at 4ºC, and then transferred to a formic acid-based 
 
 75 
decalcifier (Cal-ExII, Fisher Scientific) for 2 weeks, under mild agitation on a rocker 
plate. Following paraffin processing, 5 µm-thick mid-saggital sections were cut and 
stained with Picrosirius red [309] and Safranin-O/Fast-green [278]. Cartilage areas in 
Safranin-O sections were segmented and evaluated by using a colorimetric threshold 
(Axiovision, Carl Zeiss, Germany). Manual contouring of lamellar and woven bone areas 
in ImageJ [310] allowed comparison of organization and maturity in Picrosirius red 
sections. 
Finite Element Modeling 
 MicroCT-generated reconstructions of three representative defects per group were 
subjected to finite element (FE) analysis following voxel to element conversion (voxel 
size: 42 µm), and the spatial and frequency distributions of maximum and minimum 
principal strains were determined under physiologic loads. Rat femoral loads caused by 
gravitational impact during ambulation have previously been estimated as one half the 
body weight (BW) [311]; however, there is increasing evidence that muscle contraction 
loads contribute significantly to adaptive signals [312]. Therefore, in vivo femoral loads, 
Pfemur, were assumed to be axially-oriented at a magnitude of 1.0 BW. Traction 
boundary conditions on the in-grown bone, Pdefect, were then determined by the “rule of 








 ,    (Eqn. 4.1) 
where ki = axial stiffness of the i
th 
species, and Pi = axial load on the i
th
 species, for both 
stiff and compliant plate samples. A sensitivity study was conducted to evaluate the effect 
of error in femoral load estimation on local mechanical conditions. The cortical bone 
ends were segmented and given a modulus of 10 GPa [313], while the newly-formed 
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bone properties were determined by back-calculation from physical tests. The Poisson 
ratio was assumed to be 0.33. 
To estimate a modulus for newly-formed bone, separate samples were tested 
nondestructively in axial compression to an effective strain of 1200 µstrain. Axial loads 
and effective defect strains, measured by laser extensometer (LX 500, MTS, Eden Prairie, 
MN), were used to determine axial stiffness (kactual). Corresponding microCT 
reconstructions were subjected to the analogous FE analysis to yield an axial stiffness 
(kFE) based upon an arbitrary elastic modulus (EFE = 2000MPa). Linear correlation 







EE        (Eqn. 4.2) 
Statistical Analyses 
 All data are presented as mean ± standard error of the mean (SEM). Differences 
between groups, among time points, and among spatial regions, accounting for animal 
variability, were assessed by two- and three-factor analysis of variance (ANOVA), as 
appropriate. Individual comparisons were made by Tukey‟s post hoc analysis. 
Comparison of regression lines was performed by analysis of covariance (ANCOVA). A 
p-value < 0.05 was considered significant. Minitab® 15 (Minitab Inc., State College, PA) 
was used to perform the statistical analysis. A list of analyses performed and associated 






Table 4.2: Analyses performed and sample sizes for both stiff and compliant plate 
groups. 
Analysis Method Time Points (week) N (per group) 
Faxitron 4, 8, 12 10 
MicroCT 4, 8, 12 8 
Mechanical Testing 12 8 
Histology 5 1 
Histology 12 1 




Faxitron radiographs taken at weeks 4, 8 and 12 post-surgery confirmed that both 
stiff and compliant plates maintained limb stability, and the delivered growth factor 
induced bridging of the defects prior to compliant plate actuation at week 4, with bone 
completely filling the defect space by week 12 (Figure 4.3).  
 
Figure 4.3. Representative digital radiographs taken at weeks 4, 8 and 12 post-surgery. 
The compliant plate was locked until plate actuation at week 4, followed by 8 weeks of 





In vivo microCT scans were performed every four weeks post-surgery. Prior to 
compliant plate actuation at week 4, the bone volume was not significantly different 
between groups; however, after 4 weeks of load transfer, at week 8, the compliant plate 
group featured a significantly greater bone volume than the stiff plate group, and this 
difference continued through week 12 (Figure 4.4A). Though both groups featured a 
continuous increase in mean density throughout the experiment, there were no differences 
in mean density between groups at any time point (Figure 4.4B). Three-dimensional 
reconstructions of the defects at week 12 demonstrated qualitative differences in bone 
distribution as a function of axial position (Figure 4.4C), though the local density 
distribution within the defect did not change along the bone axis or between groups 




Figure 4.4. MicroCT analysis. Bone volume (A) and mean density (B) at weeks 4, 8, and 
12 post-surgery. Bone formation was significantly increased after 4 weeks of loading in 
the compliant plate group over the stiff plate group. (C): Representative 3D 
reconstructions of limbs qualitatively demonstrated a difference in distribution between 
the proximal and distal ends of the defects. (D): Local density mapping on saggital cross 
sections illustrated internal distribution and maturity.  
 
Biomechanical Testing 
Post mortem mechanical testing was performed to assess the degree of functional 
regeneration of the limbs. Torsion tests demonstrated a significant 58.2% increase in 
torsional stiffness as a result of compliant fixation (Figure 4.5A); however, loading did 






Figure 4.5. Biomechanical testing. Torsional stiffness (A), but not maximum torque at 
failure (B), was significantly enhanced by compliant fixation. 
 
Bone Distribution 
Compliant fixation resulted in a significant 30.4% increase in average polar 
moment of inertia (pMOI, Figure 4.6A). To quantify the location dependence of the bone 
distribution, the pMOI was graphed as a function of position from the defect center, x 
(Figure 4.6B). In both groups, linear regression indicated a significantly positive slope in 
pMOI vs. x (from distal to proximal end). The regression lines differed significantly, with 
the compliant plate group having both greater slope and intercept (Stiff: m=4.35 ± 0.386, 
b = 56.69 ± 1.05, R
2




As each data set more closely approximated a tri-phasic curve, with inflection 
points at the native bone ends, the pMOI values were binned into three regions, 
determined by the edges of the defect (Figure 4.6C). At the distal end, where the pMOI 
was a minimum, there was no significant effect of loading on bone distribution; however, 
in both the defect and proximal regions, loading significantly increased the bone 




Figure 4.6. Moment of inertia analyses. (A): MicroCT revealed a significantly greater 
average polar moment of inertia (pMOI) in the compliant plate group at week 12. (B): 
Graph of local pMOI vs. distance from defect center quantitatively verified differences in 
distribution as a function of position. Also, the slopes of regression lines were 
significantly different between the two groups. (C): Illustration of regions used for 
binning data from B. (D): Comparison of average pMOI in each region, demonstrating no 
differences in distribution at the distal end where the pMOI was a minimum.  
 
Histology 
At weeks 5 and 12 post-surgery, one sample from each group was selected for 
histology. Picrosirius red staining, whose birefringence is specific for collagen [309], was 
performed to compare the local tissue organization and degree of cell-mediated 
remodeling between groups at weeks 5 and 12 post-surgery. When viewed under 
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polarized light, the collagen fibers become birefringent and distinguish organized 
lamellar bone from unorganized woven bone. Comparison of lamellar and woven bone 
areas qualitatively revealed no differences between groups after 1 week of loading, at 
week 5 (Figure 4.7A, B); however, by week 12, the stiff plate group had a greater 
proportion of lamellar bone, indicating a more remodeled architecture, while the 
compliant plate group appeared unchanged (Figure 4.7C, D). 
 
Figure 4.7. Picrosirius red-stained histology images, viewed under polarized light to 
highlight collagen I organization. (A): Stiff plate group at week 5. (B): Compliant plate 
group at week 5. (C): Stiff plate group at week 12. (D): Compliant plate group at week 
12. Qualitatively, no differences were observed at week 5, one week after load initiation; 
however, a qualitatively greater proportion of lamellar bone was evident in the stiff plate 
group compared to the compliant plate group at week 12. Images are representative, 
selected based on average ratio of woven bone area:total bone area. Scale bars: 50µm.  
 
Safranin-O/Fast-green revealed positive staining for cartilage in both groups and 
at both time points (Figure 4.8A-F). Cartilage appeared predominantly at the distal end of 
the defect, and very little cartilage staining was found near the proximal end (Figure 
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4.8A, B). In the limited number of samples evaluated, Safranin-O staining qualitatively 
demonstrated a larger amount of cartilage in the compliant plate samples compared to the 
stiff plate samples. At week 5, hypertrophic chondrocytes were evident at the edges of 
cartilage islands and embedded in mineralized matrix, suggesting an endochondral 
ossification process (Figure 4.8C, D). Comparatively, very few glycosaminoglycan 
(GAG)-secreting chondrocytes remained by week 12, and most remaining hypertrophic 
chondrocytes were fully surrounded by mineralized matrix (Figure 4.8E, F). Alginate gel 
also stained red but was acellular and therefore easily identifiable (Figure 4.8E, F).   
 
Figure 4.8. Safranin-O/Fast green-stained histology images at week 5 and 12 post-
surgery. (A, B): Cartilaginous tissue at distal end of stiff and compliant plate groups, 
respectively, at week 5. Scale bars: 500µm. (C, D): Boxed areas from A and B, 
respectively, demonstrating hypertrophic chondrocytes and bone/cartilage interface. 
Scale bars: 100µm. (E, F): Hypertrophic chondrocytes (white arrows) embedded in 
mineralized matrix from compliant and stiff plate groups, respectively, at week 12. 
Qualitatively, a greater amount of cartilage formation was found in the compliant plate 
group, and in all samples, cartilage formation occurred predominantly at the distal end of 




Finite Element Modeling 
Back-calculation of material properties from physical tests as described in 
methods determined the average tissue modulus for regenerate bone at week 12: Eactual = 
628.43 ± 54.47 MPa. The in vivo defect loads, Pdefect, were calculated to be 48% greater 
in the compliant plate group at week 12 (Stiff: 2.00 ± 0.18 N; Compliant: 2.95 ± 0.06 N, 
p=0.0072). Finite element analyses were then performed using these material properties 
and boundary conditions to assess the local stress/strain state under the different loading 
conditions at week 12 (Figure 4.9). Despite the greater load magnitudes in the compliant 
plate group, FEA demonstrated that the average principal strains were not different 
between the two groups (Figure 4.9A), which suggests an adaptive response in the 
compliant plate group to minimize overstrain by adding material. Accordingly, the FEA-
derived apparent modulus of the compliant plate group was significantly increased over 
the stiff plate group (Fig 4.9B). This effect is further illustrated in the representative 





Figure 4.9. Finite element modeling at week 12: Local minimum principal strain 
mappings for stiff and compliant plate groups, respectively (A, B). Despite a greater 
amount of load transfer in the compliant plate group, the average principal strains were 
not different between groups (C). Accordingly, the apparent-level modulus was 
significantly greater in the compliant plate group (D). 
  
At week 12, the minimum and maximum principal strains ranged from 
approximately -500 to 300 µstrain, respectively, for both groups, but the frequency 
distribution of these strains throughout the defect was significantly different between the 
groups (Figure 4.10). In the stiff plate group, a larger proportion of voxels carried very 
low strains (Figure 4.10A); whereas, in the compliant plate group, strains were more 
evenly distributed (Figure 4.10B). These observations were quantified by analysis of the 
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kurtosis of the distribution, a measure of the peakedness of a curve. The kurtosis was 
significantly greater in the stiff plate group, indicating a more peaked distribution, 




Figure 4.10. Principal strain histogram analysis. Frequency distributions of principal 
strains indicated that local strains were more evenly and efficiently distributed in the 
compliant plate group (A, B). Differences in distribution curves were quantified by 
kurtosis analysis (C). The kurtosis was significantly greater in the stiff plate group, 
indicating a more peaked distribution, whereas the compliant group had a flatter 
distribution. 
 
Non-destructive Prediction of Biomechanical Properties 
Finally, the ability of the non-destructive microCT and FEA to predict the elastic 






physical and virtual test parameters. Bone volume alone was a poor predictor of 
biomechanical properties (Figure 4.11A, B). Including the cross sectional distribution 
through the average polar moment of inertia increased the explanatory power (Figure 
4.11C, D); however, the best predictor of mechanical strength was the apparent modulus 
calculated by FE analysis, which predicted 78 and 59% of the variation in torsional 





Figure 4.11. Correlations between physical tests and microCT and FEA parameters. (A, 
B): Torsional stiffness and maximum torque vs. bone volume. (C, D): Torsional stiffness 
and maximum torque vs. average pMOI. (E, F): Torsional stiffness and maximum torque 
vs. FEA-derived apparent modulus. The predictive power is increased by use of FEA 




This study demonstrated that manipulation of fixation stiffness during the course 
of segmental bone defect healing significantly influences the amount, distribution, and 
biomechanical properties of regenerated bone within the defect. In this experiment, limbs 
were stabilized with either stiff plates or compliant plates designed to transfer axial loads 
to the ingrowing bone while resisting transfer of torsional and bending moments. Axial 
loading significantly increased bone formation and cross-sectional distribution, 
conferring a significant enhancement in elastic stiffness, but did not alter the maximum 
torque at failure or work to failure.  
These observations may be explained by application of simple mechanics of 
materials theory to the distribution data. While loading significantly increased the 
average pMOI, it did not alter bone distribution at the distal end, where failure during 
biomechanical testing was observed. Assuming that the tissue modulus did not vary by 







 ,      (Eqn. 4.3) 
where G is the elastic shear modulus, Javg is the average pMOI, and L is the gage length 
of the test. Thus, an increase in average pMOI, induced by mechanical stimulation, would 
cause a proportional increase in stiffness. Failure, however, occurs when the maximum 
shear stress reaches a critical value. The maximum shear stress in the limb is related, not 





 ,      (Eqn. 4.4) 
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where T is the torque, and r is the outer radius at the location of Jmin, the minimum pMOI. 
Since loading did not alter bone distribution at the distal end, where the pMOI was a 
minimum, the failure properties were not affected by loading.  
 For comparison, the mechanical properties of age-matched intact femurs were 
0.030 ± 0.001 N-m/deg and 0.31 ± 0.02 N-m for torsional stiffness and failure torque, 
respectively [276]. A previous study using the same protein delivery system with 5 µg 
rhBMP-2 in 8 mm defects reached about 75% of intact bone properties for both stiffness 
and torque, though these were not statistically different from the native bone properties 
[314]. In this study, with a 6 mm defect, the stiffness and failure torque of the stiff plate 
group were similar to intact bone; however, in the compliant plate group, the torsional 
stiffness was significantly greater than that of the unoperated limbs. 
The observed axial variation in distribution, regardless of fixation type, may be 
due to a variation in vascular supply, which could affect the availability of 
osteoprogenitor cells. Given a sufficient vascular supply, mesenchymal stem cells 
(MSCs) can differentiate into bone forming osteoblasts; however, in hypoxic 
environments, they may preferentially differentiate into chondrocytes [315]. Accordingly, 
in this experiment, positive staining for cartilage was evident primarily at the distal end 
of the defects, suggesting locally reduced perfusion. Likewise, in agreement with the 
strain-mediated tissue differentiation theories proposed by Carter, Perren, and others, 
more cartilage was found in loaded samples, at both week 5 and week 12 [148, 301]. This 
finding agrees with other in vivo model systems in which mechanical stimulation altered 
the tissue differentiation profile and prolonged the chondral phase of the endochondral 
ossification process [110, 140, 316].  
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rhBMP-2 can induce intramembranous or endochondral ossification, depending 
on various factors including anatomic location [97, 317]. Unlike the mechanical 
instability studies performed on bone fractures or non-critically sized osteotomies [109-
111, 149], these segmental bone defects did not display exuberant external callus 
formation in either group. The compliant fixation plates, while allowing axial load 
transfer did not result in mechanical instability. However, we have found in a separate 
study that if the uniaxial constraint is removed, allowing multi-modal loading, these 
defects progress to nonunion as a result of instability [276]. With stable plates (either stiff 
or axially compliant), there appears to be more inconsistent formation of cartilage and a 
combination of intramembranous and endochondral bone formation, though the 
mechanical stimulus may increase or prolong endochondral ossification.  
The interactions between rhBMP-2 and mechanical loading were not directly 
investigated in this study. Bmp-2 mRNA expression has been shown to increase in 
response to mechanical stimulation in vitro [232, 318], and the effects of rhBMP-2 
delivery to non-critically sized fractures has been shown to be dependent upon 
mechanical conditions [319], however these interactions are not well understood, 
especially in large bone defects which require biologic treatment. In this model, empty 
and nanofiber mesh-only defects filled with fibrous tissue resulting in non-union; 
therefore, a group with loading but not rhBMP-2 was not included. However, 
unpublished preliminary data suggest that at lower doses of rhBMP-2 which do not 
induce bridging, an effect of loading is not apparent. Future work will address these 
potentially important interactions.  
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 In addition to differences in tissue composition, there was a location-dependent 
response to functional loading, such that the proximal and defect regions experienced a 
significant increase in bone distribution as a result of loading, while the distal region was 
not affected. While a possible explanation is spatial inhomogeneity in the mechanical 
environment, there were no significant differences in principal strains between the 
proximal and distal ends (data not shown). Therefore, this location-dependence may have 
been caused by a less favorable vascular environment for progenitor differentiation at the 
distal end, which would provide fewer mechanosensitive cells to respond to the local 
mechanical stimulus. 
Finite element modeling allowed back-calculation of the local material properties 
of tissue-engineered bone. This value (628.43 ± 54.47 MPa), is substantially lower than 
reported values for rat cortical bone, which are on the order of 10 GPa [313], however it 
is very similar to the reported tissue modulus of woven bone (approximately 600 MPa) 
[306]. While the boundary conditions were calculated based on femoral loads equal to the 
body weight, a sensitivity analysis assuming one order-of-magnitude error in boundary 
conditions yielded corresponding 10-fold differences in strain magnitude, but did not 
affect the strain distribution patterns presented. The flattening of the frequency 
distribution curve in the compliant plate group indicates that strains are distributed over 
more voxels, suggesting that these samples had adapted to more efficiently carry the 
applied loads. The observed alterations in tissue maturity suggest that the assumption of 
homogeneity of the bone tissue incurs some error, however, taking this into account, the 
greater amount of lamellar bone in the stiff plate group would tend to enhance these 
differences in strain distribution by including regions of increased tissue modulus. 
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This study also demonstrated that the FE method can be applied to non-
destructively predict mechanical properties in segmental bone defect repair. This expands 
on the work of Reynolds and colleagues, who used microCT-generated structural 
parameters to predict biomechanical properties of allograft-treated segmental defects 
[320]. Though the current correlation study featured relatively small sample sizes, similar 
correlation coefficients to those reported by Reynolds et al. were found for structural 
parameters; however, FEA resulted in significantly improved prediction of mechanical 
properties due to inclusion of not only volume and distribution, but also geometry, 
connectivity, and tissue-level properties through the FE-derived apparent modulus. This 
approach allows researchers to evaluate mechanical properties of samples reserved for 
other end-point analyses, such as histology. Also, as clinical CT systems continue to 
improve in resolution, this approach may allow for noninvasive, longitudinal evaluation 
of functional regeneration in patients, where mechanical testing is clearly precluded. 
One assumption made in the FE modeling was that mechanical loading did not 
alter the local elastic material properties. While the mean density was not affected by 
loading, load-mediated adaptive modeling did alter the microstructural maturity. This was 
assessed by comparison of collagen organization, which demonstrated that loading 
prolonged the presence of woven bone. This suggests potentially lower tissue-level 
material properties in the loaded samples compared to those with stiff plates, as it has 
been shown that lamellar bone has a higher tissue modulus than woven bone [306], and 
accentuates the observed differences in local strains and structural properties between 
groups. This load magnitude-dependent modulation of bone maturity has been observed 
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previously [306], and could be a result of increased or prolonged osteoblast activity or 
reduced osteoclast activity.  
A limitation of the microCT-based approach is that only mineralized tissues can 
be evaluated. Therefore, the soft tissue inhomogeneities including cartilage and fibrous 
tissue were not included in the FE models or moment of inertia calculations, which 
modeled non-mineralized matrix as voids. However, at the time point of FE modeling, 
MOI analysis, and mechanical testing, week 12, the amount of cartilage in the defects 
was minimal and therefore not likely to dominate the behavior. Likewise, the differences 
in modulus between these soft tissues and bone further suggest that the mineralized 
matrix is likely the primary contributor to the structural properties. Similarly, the simple 
mechanics of materials analysis did not include the inhomogeneity of the tissue. 
However, this procedure was not performed to determine values, but rather to 
mathematically explain the experimental observations that an increase in average polar 
moment of inertia led to increases in stiffness, while the lack of change in minimum 
moment of inertia resulted in no differences in maximum torque. Therefore, despite the 
above simplifications, this analysis qualitatively explained these observations. 
In conclusion, this study demonstrated that functional transfer of axial loads by 
modulation of fixation plate stiffness significantly alters BMP-mediated large bone defect 
repair by increasing bone formation and distribution and modulating tissue organization 
and differentiation. Consideration of the mechanical environment may therefore improve 
clinical treatment of challenging segmental bone defects as well as advance our 
understanding of the role of biomechanical factors in bone tissue differentiation, 
formation, and remodeling. 
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CHAPTER V: EFFECTS OF IN VIVO MECHANICAL LOADING 
ON VASCULAR GROWTH IN LARGE BONE DEFECT 
REGENERATION 
ABSTRACT 
Bone regeneration is a major challenge to orthopaedic surgeons, and poor 
vascularization is one of the primary factors limiting current treatment strategies for bone 
defect healing. We have previously demonstrated that in vivo mechanical loading 
enhances bone regeneration in a critically-sized rat femoral defect model; however, the 
effects of mechanical loading on neovascular growth in large bone defect repair have not 
yet been studied. Therefore, we evaluated the effects of early and delayed functional 
loading on vascular growth using axially compliant fixation plates which were electively 
actuated to allow ambulatory load transfer either at the time of implantation (early), or 
after 4 weeks of stiff fixation (delayed). Neovascular growth and bone regeneration were 
evaluated at week 3 following the onset of loading by contrast-enhanced microcomputed 
tomography and histology. Early loading significantly inhibited vascular invasion into the 
defect and reduced bone formation by 75% in comparison to stiff plate controls. Delayed 
loading, however, significantly enhanced bone formation by 20% and stimulated vascular 
remodeling by increasing vascular thickness and reducing the number of vessels less than 
100 µm in diameter. Together, these data indicate that the early phase of bone defect 
healing is highly sensitive to the mechanical environment, and excessive 
interfragmentary motion can impair bone healing. However, under appropriate 
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Large bone defect regeneration is a major challenge in orthopaedic trauma and 
reconstruction, and poor vascularization is one of the primary factors limiting current 
treatment strategies for bone defect healing [15-16]. Structural allografts are often used to 
bridge the defects; however, there is a high post-surgery failure rate which is directly 
attributable to insufficient revascularization [15-16]. Bone is a highly vascularized tissue, 
and angiogenesis, the sprouting of new blood vessels, is essential to skeletal development 
and healing [15, 243-244]. These observations have stimulated great interest in 
developing treatments which induce both bone regeneration and neovascularization.  
Similar to bone cells, which are highly mechanosensitive and coordinate to 
adaptively remodel bone matrix, endothelial cells and vascular networks respond 
dynamically to mechanical stimuli, including both fluid-induced shear stress and 
mechanical strain [3, 321-323]. However, the window of therapeutic effect has not yet 
been determined, and conflicting observations have been reported in vitro. For example, 
Mooney and colleagues demonstrated that 6% cyclic uniaxial strain increased endothelial 
cell tube formation and angiogenic growth factor secretion for cells cultured in two-
dimensions (2D), while in 3D, 8% strain regulated the directionality of the neovascular 
networks, but diminished new branch formation [3-4]. Others have shown that 
mechanical stretch alters the orientation of 3D microvascular networks without 
significantly affecting endothelial sprouting [322-323]. Wilson et al. found disruption of 
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endothelial network formation but increased production of pro-angiogenic proteins in 
response to 2.5% strain [324]. These observations have led to an interest in the ability of 
mechanical conditions to modulate vascularized tissue regeneration. 
In the context of bone healing, the effects of mechanical stimuli have been 
examined primarily in long bone fracture healing, in which fixation stiffness regulates the 
canonical healing patterns as a result of functional loading. In bone fractures, 
interfragmentary motion caused by non-rigid fixation stimulates endochondral 
ossification, while rigid fixation leads to intramembranous ossification [1, 105-106, 116]. 
Likewise, the timing of vascular ingrowth is also known to alter healing patterns, as early 
vascularization is associated with intramembranous ossification and delayed ingrowth 
with endochondral ossification [251]. Interfragmentary strains have been implicated as 
the driving force behind these tissue differentiation paradigms as a result of the 
homeostatic cellular response to maintain the capacity of the callus tissues to withstand 
the applied loads (i.e. Perren‟s Interfragmentary Strain Theory) [247]. However, another 
hypothesis is that mechanical disruption of vascular ingrowth initially drives avascular 
cartilaginous callus formation. Then, as the callus matures, interfragmentary motion is 
reduced, allowing initiation of vascular invasion and subsequent endochondral bone 
formation. Regardless of pathway, however, sufficient vascularization is essential for 
timely healing, and insufficient vascularization can lead to delayed healing or atrophic 
nonunion [248-249]. 
Specifically, several studies indicate that altering the local mechanical 
environment results in modified vascular ingrowth and consequent fracture healing, 
though results have been conflicting. Sarmiento et al. reported that moderate load transfer 
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enhanced vascular growth in bone fractures compared to rigid fixation [325] and Wallace 
et al. found increased corticomedullary blood flow in response to decreased fixation 
stiffness in the early stages of fracture healing but, after 6 weeks, observed a 50% 
decrease in periosteal callus perfusion [250]. In contrast, Lienau and colleagues 
demonstrated impaired vessel formation and reduced angiogenic gene expression under 
conditions of rotational and shear instability [149, 251]. Claes et al. also showed 
decreased vascular ingrowth and increased fibrocartilage formation in the presence of 
larger axial interfragmentary strains of 10 and 50% [117]. Together, these studies suggest 
a window of desired mechanical stimulus in which a moderate degree of loading is 
anabolic, but excessive loading may prevent vascular growth, with the timing of load 
application determining threshold magnitudes.  
While critically-sized segmental bone defect repair may not follow the same 
canonical patterns found in fracture healing, vascularization may play an even more 
critical role given the larger size of the defect and associated nutrient diffusion limitations 
[16]. Mechanical stimulation may therefore be a potential point of intervention to 
enhance vascularized bone defect repair by influencing vascular network formation and 
subsequent mineralization. In Chapter IV, we reported that controlled load-bearing has 
the capacity to enhance bone regeneration in BMP-mediated large bone defect repair. 
However, the effects of mechanical loading on neovascularization of segmental defects 
have not yet been studied.  
In this study, therefore, we examined the effects of loading on neovascular 
invasion and bone healing. Our overall hypothesis was that in vivo mechanical loading 
can modulate neovascular growth and bone formation. The timing of load application 
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may affect the response, however. Therefore, we evaluated the effects of both early 
(immediate actuation) and delayed loading (week 4 actuation) on vascular growth and 
bone formation. We hypothesized that early loading would disrupt nascent vessels, 
resulting in impaired bone regeneration, while delayed loading would stimulate vascular 
growth, consistent with the increased bone formation found in the previous bone 
regeneration experiment. 
 
MATERIALS AND METHODS 
Surgical Procedure 
Bilateral, critically-sized (8 mm) bone defects were surgically created in femora 
of 13-week-old female SASCO Sprague-Dawley rats (Charles River, Wilmington, MA) 
as previously described [275-276]. Limbs were stabilized by either stiff fixation plates or 
compliant plates which allowed elective actuation of axial load sharing [276] (n = 10-12 
per group). The stiff plates featured an axial stiffness of 214.3 ± 4.1 N/mm, while the 
compliant plates had a stiffness of 349.5 ± 35.1 N/mm and 8.4 ± 0.4 N/mm in the locked 
and actuated configurations, respectively [276]. Compliant fixation plates were actuated 
to allow ambulatory load transfer either at the time of initial implantation (early loading 
group) or at week 4 post-surgery (delayed loading group). Animals from each group 
received a compliant fixation plate and a contralateral stiff plate control. Animals in the 
delayed loading group received a secondary operation to actuate the compliant plates at 
week 4 post-surgery, while contralateral stiff plate controls were sham operated at the 
same time.  
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All defects were treated with recombinant human bone morphogenetic protein-2 
(rhBMP-2), delivered in a hybrid nanofiber mesh/alginate-based delivery system [14]. 
Briefly, perforated nanofiber mesh tubes were created as described previously and were 
placed over the native bone ends, surrounding the defect [14]. 150 µl of alginate hydrogel 
containing the appropriate dose of rhBMP-2 was then injected into the defect space [14]. 
Defects in the early loading group and their contralateral controls received either 0.5 or 
2.5 µg rhBMP-2. Defects in the delayed loading group and their stiff plate controls 
received 5.0 µg rhBMP-2, resulting in the 6 groups illustrated in Table 1. The doses were 
chosen based on the dose-response study described in Chapter III. In the early loading 
study, two doses were chosen: one which induces bone formation, but fails to induce 
consistent bridging of the defects (0.5 µg), and one which induces robust bone formation 
and consistent defect bridging by week 12, without over-saturating the response (2.5 µg). 
These doses were chosen to allow for either a positive or negative effect of loading on 
vascular growth. For the delayed loading study, we chose a dose (5.0 µg) which induced 
consistent bridging of the defects at week 4, the time point of compliant plate actuation. 
This dose also matched the previous mechanical loading study described in Chapter IV, 
allowing direct comparison. The 2.5 microgram dose was not used as it fails to induce 
consistent bridging of the defects by week 4 (bridging rate: 60%) (see Chapter III). The 
absence of bridging would drastically influence the amount of interfragmentary motion 















Sample Sizes for Analyses performed 















Early Stiff 0.5 - 10 - - 9 - 1 - 
Early Compliant 0.5 Day 0 9 - - 8 - 1 - 
Early Stiff 2.5 - 9 - - 8 - 1 - 
Early Compliant 2.5 Day 0 10 - - 9 - 1 - 
Delayed Stiff 5.0 Sham Day 28 12 12 12 - 11 - 1 
Delayed Compliant 5.0 Day 28 11 11 11 - 10 - 1 
 
Post-surgery, animals were given subcutaneous injections of buprenorphine every 
8 hours, 0.04 mg/kg for the first 48 h and 0.013 mg/kg for the following 24 h. All 
procedures were approved by the Georgia Institute of Technology Institutional Animal 
Care and Use Committee (IACUC, protocol # A08032).  
Alginate & Growth Factor Preparation 
 Recombinant human BMP-2 (R&D Systems, Minneapolis, MN) was reconstituted 
in 0.1% rat serum albumin in 4 mM HCl, according to manufacturer instructions. rhBMP-
2 was then mixed with RGD (Arg-Gly-Asp) peptide-functionalized alginate [224, 277] to 
a final concentration of 2% alginate, which was crosslinked by mixing rapidly with 
0.84% (m/v) CaSO4. Each defect received 150 µl of the pre-gelled alginate with 0.5, 2.5, 
or 5.0 µg rhBMP-2, depending on group (Table 1). 
Faxitron 
 Digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray Corp., Wheeling, 
IL) were performed at an exposure time of 15 s and a voltage of 25 kV. Animals from the 
early loading groups (n =10 per group), which were euthanized at week 3, received X-ray 
imaging at week 2 post-surgery to evaluate bone formation, while animals from the 




 8-11 samples from each group (Table 1) were reserved for microcomputed 
tomography (microCT) angiography. Animals in the early loading groups were 
euthanized by CO2 asphyxiation at week 3 post-surgery, while those from the delayed 
loading groups were euthanized at week 7 post-surgery (week 3 after compliant plate 
actuation). Radiopaque contrast agent-enhanced microCT angiography was performed 
using a protocol modified from Duvall et al. [326]. Briefly, a 2-inch 18-gauge catheter 
(SURFLO® Teflon I.V. Catheter, Terumo Medical, Somerset, NJ) was inserted into the 
left ventricle of the heart and advanced into the ascending aorta. The inferior vena cava 
was then severed, and 0.9% saline containing 0.4% (w/v) papaverin hydrochloride 
(Sigma-Aldrich, St. Louis, MO) was perfused through the vasculature using a peristaltic 
pump until complete clearance. The vasculature was fixed in an open configuration by 
perfusion with 10% neutral buffered formalin (NBF), which was then cleared with saline. 
Finally, 25 ml of polymerizable, lead chromate-based, radiopaque contrast agent 
(Microfil MV-122, Flow Tech; Carver, MA) was then injected using a 30 ml syringe. 
The contrast agent was prepared according to manufacturer instructions, except 
the agent was diluted to a final concentration of 66% MV-122 to allow simultaneous 
segmentation of both newly-formed bone and vascular contrast agent. Samples were 
stored at 4°C for 24 hr to allow polymerization of the contrast agent. Hindlimbs were 
then excised and stored in 10% NBF for 1 week until preliminary microCT analysis.  
MicroCT Analysis 
MicroCT scans (VivaCT 40, Scanco Medical, Basserdorf, Switzerland) were 
performed at medium resolution with a 21.0 µm voxel size at a voltage of 55 kVp and a 
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current of 109 µA. Newly formed bone and contrast agent-filled vessels were segmented 
by application of a global threshold corresponding to 386 mg hydroxyapatite/cm
3
, and a 
low-pass Gaussian filter (sigma = 1.2, support = 1) was used to suppress noise. Following 
initial microCT scanning to evaluate both new bone and perfused vessels, samples were 
transferred to a formic acid-based decalcifying agent (Cal-ExII, Fisher Scientific, 
Waltham, MA or Immunocal, Decal Chemical Co., Tallman, NY) for 2-3 weeks. 
Decalcified samples were then re-scanned using the same settings and in the same 
position as before to quantify vascular structures alone.  
 Two cylindrical volumes of interest (VOI) were contoured for analysis: a defect 
VOI (5 mm diameter x 6.3 mm length) and a total VOI (7 mm diameter x 6.3 mm 
length). The defect VOI encompassed only the nanofiber mesh and defect region, while 
the total VOI included the defect and surrounding soft tissues. The position of the VOIs 
in the pre- and post-decalcification scans was confirmed by position relative to the 
fixation plate, which did not change by decalcification. For pre-decalcification analysis, 
the volume of all attenuating tissues, including bone and contrast agent-filled vasculature 
was computed. After decalcification, the vascular volume, connectivity, thickness, 
thickness frequency distribution, number, spacing, and degree of anisotropy were 
analyzed as described previously [326]. The bone volume in the defect was then 
computed by subtraction of the vascular volume from the bone-plus-vessel volume in the 
total VOI. The vascular morphology was compared between the proximal and distal ends 
of the defects by separately analyzing each half of the defect VOI (5 mm diameter x 3.15 




 One representative sample per group was chosen for histology based on 
qualitative Faxitron evaluation of bone growth. Samples were fixed in 10% NBF for 48 
hours at 4ºC and then decalcified over 2 weeks under mild agitation on a rocker plate. 
Following paraffin processing, 5 µm-thick mid-saggital sections were cut and stained 
with Haematoxylin and Eosin (H&E) and Safranin-O/Fast-green [278].  
Statistical Analyses 
All data are presented as mean ± standard error of the mean (SEM). Differences 
between groups, accounting for animal variability, were assessed by analysis of variance 
(ANOVA) with pairwise comparisons made by Tukey‟s post hoc analysis. A p-value < 
0.05 was considered significant. Minitab® 15 (Minitab Inc., State College, PA) was used 
to perform the statistical analysis.  
 
RESULTS 
The creation of a bone defect results in a rapid and extensive angiogenic response 
in the surrounding tissues, with collateral vessel formation and growth of blood vessels 
toward the site of injury (Figure 5.1). This study evaluated the ability of early and 




Figure 5.1. Vascular response to bone injury: angiogenesis and collateral vessel 
formation. (A): MicroCT image of age-matched unoperated femur with surrounding 
vasculature. (B): Bone and vascular structures 3 weeks following creation of an 8 mm 
bone defect.  
 
Early Loading: Vascular Growth 
Vascular structures in the early loading groups at week 3 post-surgery were 
quantitatively analyzed within the defect VOI and the total VOI to include both the defect 
and the surrounding soft tissues (Figure 5.2A). There were no differences in the vascular 
volume (Figure 5.2B) or connectivity (Figure 5.2D) between groups for the total VOI; 
however, within the defect VOI, in the presence of early loading, vascular volume 
(Figure 5.2C) and connectivity (Figure 5.2E) were significantly lower by 66% and 91%, 
respectively, for the 2.5 µg rhBMP-2 dose. Similar trends were found for the 0.5 µg dose, 
though these differences did not reach statistical significance (p = 0.56 and 0.16 for 
vascular volume and connectivity, respectively). Other morphometric parameters 
including vascular thickness, separation, number and degree of anisotropy were not 
significantly altered by loading at either dose for both the total VOI and defect VOI (data 




Figure 5.2. MicroCT angiography of early loading groups. (A): Representative 3D 
reconstructions of vascular structures in the total VOI (7mm Ø) and defect VOI (5 mm 
Ø) for each dose and fixation plate type. Scale bars: 1mm. (B, C): Vascular volume in 
total VOI and defect VOI, respectively. (D, E): Vascular connectivity in the total VOI 
and defect VOI, respectively. a: p < 0.05. 
 
rhBMP-2 dose was a significant predictor in the ANOVA for both vascular 
volume and connectivity in Figure 5.2, and within the total VOI, there were no 
differences between the stiff and compliant plate groups.  Therefore, to assess the BMP-
mediated vascular response to injury, the stiff and compliant plate groups were pooled 
based on rhBMP-2 dose and compared to age-matched unoperated control limbs (n = 12; 
Figure 5.3).  The increased dose of rhBMP-2 significantly enhanced vascular network 
formation. Also, the newly formed vascular networks differed significantly from native 
architecture.  The BMP-mediated angiogenic response to injury resulted in increased 
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vascular volume, connectivity, and thickness compared to unoperated controls (Figure 
5.3B-D); however, while native vessels exhibited transverse isotropy with preferential 
alignment along the longitudinal axis, the newly formed vascular networks were 





Figure 5.3. BMP-mediated vascular response to bone injury. (A): Representative total 
VOI images of pooled stiff & compliant plate groups at each dose and age-matched 
unoperated controls. (B): Vascular volume. (C): Vascular connectivity. (D): Vascular 





 The spatial distribution of blood vessels in the stiff plate groups was analyzed by 
comparing proximal and distal volumes of interest within the defect VOI (Figure 5.4A). 
The vessel volume, connectivity, and thickness were significantly greater at the proximal 
end of the defects than at the distal end (Figure 5.4B-D, respectively).  
 
 
Figure 5.4. Spatial inhomogeneity of vessel distribution in the defect VOI of the stiff 
plate group. (A): Representative perfused image showing proximal and distal regions of 
the defect. (B-D): Vascular volume (B), vascular connectivity (C), and vascular thickness 
(D) in the distal and proximal regions. a: p < 0.05 vs. distal region. 
 
Early Loading: Bone Formation 
Bone formation within the defect responded to early loading in a similar manner 
to vascular growth (Figure 5.5). Qualitative evaluation of bone formation at week 2 post-
surgery was performed by digital radiography, illustrating reduced bone formation in the 
compliant plate group at the 2.5 µg dose (Figure 5.5A). MicroCT reconstructions of 
undecalcified perfused samples allowed simultaneous visualization of bone formation 
and vasculature at week 3 and confirmed the radiographic observations (Figure 5.5B). 
Following subtraction of the vascular volume in the defect, microCT quantification 
revealed a significant 75% decrease in bone volume in the compliant plate group 
compared to the stiff plate group at the 2.5 µg rhBMP-2 dose (Figure 5.5C). Differences 








Figure 5.5. Digital X-ray and microCT evaluation of bone formation in early loading 
groups. (A): Radiographs of limbs at week 2 post-surgery. (B): MicroCT reconstructions 
of undecalcified, perfused samples at week 3 post-surgery showing both bone formation 
and vascular growth. Scale bars: 1mm. (C): Quantification of bone volume alone. a: p < 
0.05 vs. all other groups; b: p = 0.09. 
 
Early Loading: Histology 
The high eosinophilicity of erythrocytes allowed identification of blood vessels in 
H&E stained sections (Figure 5.6). Vessel size and area density qualitatively correlated 
with microCT angiography (Figure 5.7A). In representative samples analyzed for 
histology, the stiff plate groups demonstrated qualitatively more and larger blood vessels 
than the compliant plate groups. 
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Safranin-O staining demonstrated that early loading altered tissue-biomaterial 
interactions (Figure 5.7B). In the stiff plate groups, formation of connective and 
mineralized tissues were well-integrated with alginate islands; however, in the loaded 
groups, the predominantly soft tissues that populated the defect failed to adhere to the 
alginate gel, resulting in void formation around the biomaterial. 
The presence of cartilage and endochondral bone formation was also evident in all 
four groups; however, the metabolic activity of the chondrocytes appeared to be altered 
by the mechanical environment (Figure 5.7C). Chondrocytes were present in both stiff 
and compliant plate groups, but the dark red staining of GAGs was more evident in the 
compliant plate groups. Likewise, the amount of cartilage formation was also 




Figure 5.6. 63x magnification image of H&E-stained section showing erythrocytes 






Figure 5.7. Week 3 histological staining of saggital sections of early loading groups. (A): 
Haematoxylin and Eosin-stained sections allowed identification of blood vessels by dark 
staining of erythrocytes (white arrows). Images at 20x. (B):  Safranin-O/fast green-
stained sections illustrating disruption of alginate (a) integration with surrounding tissues 
(green). Images at 10x. (C): Safranin-O/fast green-stained sections illustrating cartilage 




Delayed Loading: Vascular Growth 
Vascular structures in the delayed loading groups at week7 were quantitatively 
analyzed both within the defect and total VOIs (Figure 5.8). There were no differences in 
vascular volume between the stiff and compliant plate groups for either total or defect 
VOI (Figure 5.8B); however, vascular connectivity (Figure 5.8C) and vascular number 
(Figure 5.8D) were significantly lower in the compliant plate group for both total and 
defect VOIs. While differences in vascular thickness did not reach significance in the 
defect VOI (p = 0.08), the compliant plate group had a significantly greater vascular 
thickness in the total VOI (Figure 5.8E). In the defect VOI, the frequency distribution 
indicated a significantly lower number of small vessel bins (40-100µm in diameter; 
Figure 5.8F) and an extension of large diameter bins (315 – 441 µm in diameter; Figure 




Figure 5.8. MicroCT angiography of delayed loading groups. (A): Representative 3D 
reconstructions of vascular structures in the total VOI (7mm Ø) and defect VOI (5 mm 
Ø) for both fixation plate types. Scale bars: 1mm. (B-E): Vascular morphology 
parameters in the total and defect VOIs: vascular volume (B), vascular connectivity (C), 
vascular number (D), and vascular thickness (E). (F): Vascular thickness histogram 
indicating blood vessel size distribution. Inset: magnification of 252 - 462 µm bins. a: p < 





Delayed Loading: Bone Formation 
Unlike early loading, delayed mechanical loading enhanced bone formation 
(Figure 5.9). Digital radiography revealed that all defects had bridged with bone prior to 
plate actuation at week 4, and at this time the stiff and compliant plate groups featured 
qualitatively similar bone formation. At week 7, however, after 3 weeks of loading, there 
was qualitatively more bone formation in the compliant plate group (Figure 5.9A). Post-
mortem microCT analysis allowed reconstruction of the combined bone and vascular 
structures (Figure 5.9B) and, following subtraction of vascular volumes, revealed a 





Figure 5.9. Digital X-ray and microCT evaluation of bone formation in delayed loading 
groups. (A): Radiographs of limbs at weeks 4 and 7 post-surgery. (B): MicroCT 
reconstructions of undecalcified, perfused samples at week 7 post-surgery showing both 
bone formation and vascular growth. Scale bars: 1 mm. (C): Quantification of bone 
volume alone. a: p < 0.05. 
 
Delayed Loading: Histology  
 Histological staining at week 7 revealed substantial osteocyte-populated woven 
bone formation and strong integration of new bone formation with regions of alginate gel 
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(Figure 5.10A, B).  Individual hypertrophic chondrocytes and small remnants of 
endochondral bone formation were evident in both groups (Figure 5.10C). 
 
Figure 5.10. Week 7 histological staining of saggital sections of delayed loading groups. 
(A): H&E-stained sections illustrate bone formation (b) and regions of alginate (a). 
Images at 20x; scale bars: 50 µm. (B): H&E (top) and Safranin-O/fast green (bottom)-
stained sections illustrating bone & alginate integration. Images at 63x; scale bars: 10 
µm. (C): Safranin-O/fast green-stained sections illustrating remnants of cartilage (c) and 




This study investigated the effects of in vivo mechanical loading on 
neovascularization and bone formation in critically-sized bone defect regeneration. 
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Previously published reports indicate that mechanical conditions in the initial phase of 
bone fracture healing direct and determine the repair process [109]. We have also shown 
in Chapter IV that in large bone defects, delayed loading enhances bone regeneration. In 
this study, we evaluated the effects of both early and delayed mechanical loading on 
vascular growth and bone regeneration. 
Early Loading 
In the presence of early loading, the vascular supply in the defect was drastically 
reduced compared to stiff plate controls, but the overall angiogenic response to injury 
was not altered: the vessel volume and connectivity in the total VOI were not affected, 
suggesting that loading had a localized effect that inhibited ingrowth of vessels into the 
defect. These inhibitory effects were likely due to excessive interfragmentary motion 
associated with loading prior to defect stabilization by bone formation. In native bone 
tissue, matrix strains typically reach 0.3% [327]; however, under the loading conditions 
determined for this model (see Chapter IV), early loading resulted in initial axial 
interfragmentary strains of 5-10%, assuming negligible contribution of the mesh/alginate 
construct to defect stability. It was these relatively large initial strains that likely inhibited 
blood vessel ingrowth and bone formation in the compliant plate groups. In addition to 
disrupting vascular invasion, and inhibiting bone formation, early deformations within 
the defect may have promoted tissue differentiation toward more fibrotic and 
cartilaginous tissue types, which are inherently less vascularized. This second explanation 
has been proposed by Perren and Carter and colleagues to explain the effects of loading 
on bone fracture callus differentiation [146, 247]. In this model, mechanical loading 
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stimulates tissue formation and differentiation and vessels form and remodel to support 
the new tissues.  
Qualitative differences in cartilage metabolic activity were observed as a result of 
early loading. Though cartilage was present in all groups at week 3 post-surgery, loading 
appeared to increase or prolong GAG production, as indicated by the intensity of 
Safranin-O staining. This is consistent with our prior observations in Chapter IV and 
previous reports in the literature that mechanical loading prolongs the chondral phase of 
endochondral ossification in defect healing [110]. In Chapter IV, we also observed spatial 
variations in cartilage formation and response to loading between proximal and distal 
ends of the defects. We hypothesized that these differences were to due to proximal-distal 
inhomogeneity of the vascular distribution, with reduced vascular supply at the distal end 
of the defects. Our current study confirmed this hypothesis, showing a significantly lower 
vascular volume, connectivity and thickness at the distal end of the defects compared to 
the proximal end. The reason for this spatial variation in vascular invasion may be 
attributed to the greater surrounding soft tissue coverage at the proximal end. 
In this study, two different doses of rhBMP-2 were evaluated: a non-bridging 
dose (0.5 µg) and a dose which induces consistent defect bridging by week 12 (2.5 µg) 
(see Chapter III). The lower dose was insufficient to induce robust bone formation over 
the time course studied, and did not yield significant differences as a result of loading. 
However, mechanical loading drastically effected both vascular growth and bone 
formation at 2.5 µg. Independent of loading conditions, vascular growth responded in a 
dose-dependent manner to rhBMP-2 by week 3. The mechanisms by which BMP-2 may 
induce vascular growth remain unclear, but reports of direct angiogenic effects on 
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endothelial cells [328-329] and paracrine upregulation of VEGF expression in osteoblasts 
[330] have been reported. Overall, the vascular response to injury resulted in networks 
with greater volume, connectivity and isotropy than native un-injured tissue. 
Delayed Loading 
Delayed mechanical loading significantly enhanced bone formation, consistent 
with our previous findings in Chapter IV. Unlike early loading, it also allowed growth of 
blood vessels into the defect, as evidenced by the equivalent vascular volume in both the 
stiff and compliant plate groups. Delayed loading reduced vascular number and 
connectivity and increased vessel thickness, with a reduction in the number of small 
vessels (40 - 100 µm in diameter) and an expansion of large vessels (315 – 441 µm in 
diameter) in the compliant plate group relative to stiff plate controls. This suggests 
loading may have induced vascular remodeling to maintain defect perfusion and vascular 
volume by increasing vessel size and pruning small vessels that were no longer 
necessary, though vascular rarefaction was not directly measured. Together, these data 
suggest that delayed mechanical loading may have stimulated vascular remodeling 
through arteriogenesis, the growth and dilation of existing arterioles by proliferation of 
endothelial and smooth muscle cells [331]. This is contrary to our hypothesis that delayed 
mechanical loading would stimulate angiogenesis and growth of new vessels; however, 
these results are consistent with previous observations of vascular remodeling in rodent 
models of hindlimb ischemia, which have shown that while angiogenesis is governed 
primarily by tissue ischemia, arteriogenesis is likely regulated by biomechanical factors 
including luminal shear and vessel strain [242, 326, 332]. Similarly, Cao et al. 
demonstrated that the transition between maintenance and regression of new vessels is 
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dependent on exposure to growth factors at the time of vessel birth, and these same 
factors, PDGF, FGF, VEGF, are regulated by mechanical conditions [4, 333-336]. Thus, 
delayed mechanical loading may have accelerated the maturation and remodeling of new 
vessels, enhancing bone formation and limb regeneration.  
The results of this study indicate that neovascular network formation and growth 
may be regulated by mechanical conditions in vivo, and extravascular matrix 
deformations may alter vessel formation and remodeling to regulate engineered tissue 
regeneration. These data also suggest that the timing and magnitude of loading are 
important variables that warrant further research to determine a window of therapeutic 
effect. Recently, Kilarski et al. demonstrated that endogenous fibroblasts and 
myofibroblasts recruited during wound healing exert tensile stresses that regulate 
nonangiogenic expansion of blood vessels into fibrinogen/collagen scaffolds implanted 
onto chick chorioallantoic membranes [337]. In that study, however, mechanical 
conditions were neither measured nor directly controlled. The present study demonstrates 
for the first time that in vivo biomechanical stimulation may further enhance 
vascularization of engineered tissues. 
These experiments cannot uncouple the effects of mechanical forces on vascular 
growth and tissue formation and differentiation. Osteogenesis and angiogenesis are 
linked on a molecular level, and it is not possible to induce bone formation without 
vascular ingrowth [15]. In growth plate development, for example, expression of 
angiogenic factors precedes vessel formation, chondrocyte hypertrophy, and ultimately 
bone formation [5]. Regulation of the genes and signaling molecules important for the 
genesis of cartilage, bone, and vasculature, such as Indian Hedgehog (Ihh), Runx2, and 
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VEGF, respectively, are shared such that knock-out animals lacking any of these three 
genes experience defects in each of the three tissues, suggesting a fundamental link 
between tissue formation and vascular growth [5].  
Delayed loading may have induced remodeling simply by disrupting small vessel 
formation, which in turn reduced connectivity and vascular number, without disrupting 
the larger vessels that had developed prior to the onset of loading, allowing sufficient 
vascular supply for bone formation. However, the observed enhancements in bone 
formation suggest an increased vascular demand, requiring an improved functional 
network. Reports in the literature that mechanical loading primarily alters vascular 
remodeling over angiogenesis in various bioreactor systems corroborate this hypothesis 
[3, 322-323, 338]. Likewise, beneficial effects of loading on vascular growth have been 
observed in the bone fracture healing literature [29-30]. Further research is required to 
determine whether matrix deformations directly enhanced vascular network remodeling 
and arteriogenesis or merely disrupted new vessel formation. Such studies may have 
implications for the engineering of vascularized tissues both in the context of bone repair 
and in general. 
Histological analysis revealed close integration of the alginate and newly formed 
bone, and consistent with previous observations, the mechanical environment may have 
regulated the progression of endochondral bone formation and cartilage hypertrophy 
[110]. These observations suggest that the mechanical environment is an important 
regulator of tissue formation and differentiation in large bone defect repair.  
 There are several limitations of the methodology employed in these experiments. 
The microCT angiography technique is an end-point measure, which requires 
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decalcification of the bone, precluding longitudinal evaluations and biomechanical testing 
of the limbs for functional assessment. Thus, the time points for analysis must be chosen 
carefully, and the effects of treatment on restoration of biomechanical function must be 
performed separately (see Chapter IV). In this study, vascular structures were analyzed 3 
weeks after load initiation. This was chosen to provide sufficient time for vascular growth 
and remodeling in response to loading while perhaps capturing transient effects as well. 
Another potential limitation of this method is that the bone volume was not computed 
directly; however, care was taken register placement of the contours relative to the 
fixation plates to maintain a constant volume of interest for each scan. Finally, as 
discussed in detail by Duvall et al., the scan resolution chosen may affect the size of 
vessels capable of being detected and segmented [326]. Although there are great 
advantages for quantitative three-dimensional analysis off vascular structures using 
microCT, the formation and distribution of small capillaries on the order of 10 µm in 
diameter could not be evaluated using this methodology. 
Conclusions 
These studies evaluated the effects of early and delayed mechanical loading on 
neovascular growth and remodeling and bone formation in large bone defects. Under 
early mechanical loading, vascular growth was reduced and bone formation mitigated in 
comparison to stiff plate controls. However, in the presence of loading delayed until after 
defect bridging, the loaded group featured vascular network remodeling and enhanced 
bone regeneration compared to controls. Together, these data demonstrate the 
mechanosensitivity of vascularized tissue regeneration vivo and highlight the potential 
for mechanical stimulation to modulate post-natal vascular growth and remodeling. 
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CHAPTER VI: SUMMARY AND FUTURE DIRECTIONS 
OVERALL SUMMARY 
While large bone defects remain a critical challenge in orthopaedic surgery, tissue 
engineering has emerged as a promising treatment strategy. One approach to tissue 
engineering, termed endogenous repair, aims to stimulate the body‟s natural regenerative 
potential to restore tissue structure and function. The studies described in this thesis 
manipulated both the biochemical and biomechanical environments to initiate and sustain 
these regenerative cascades. One of the most successful applications of tissue engineering 
to date is the delivery of osteoinductive growth factors, such as members of the bone 
morphogenetic protein family [165]. The clinical delivery method for these proteins, 
however, is inefficient as large doses are required, contributing to prohibitively high costs 
and potential complications due to protein diffusion [182]. Chapter III therefore 
characterized and evaluated a biomaterial delivery system that provides a sustained 
growth factor release profile to enhance performance and reduce the necessary effective 
dose. The influence of the biomechanical environment was then quantitatively evaluated 
using this model. 
As a dynamically adaptive, load bearing tissue, bone is highly responsive to its 
mechanical environment. As has been demonstrated in bone fracture healing, modulation 
of biomechanical conditions may enhance bone healing and neovascular growth [250, 
325]. These experimental observations have led to drastic changes in the clinical 
approach to fracture fixation [107]; however, the potential for functional loading to 
enhance the regeneration of large bone defects had not been evaluated. The governing 
hypothesis of this work was that in vivo mechanical loading can enhance bone 
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regeneration and vascular growth in large bone defects treated with sustained delivery of 
rhBMP-2. 
This hypothesis was tested using a rat segmental bone defect model using a 
variety of experimental and computational techniques. Bone formation was evaluated 
longitudinally using digital radiography and microcomputed tomography, while 
functional restoration was quantified by torsional biomechanical testing and microCT 
image-based finite element modeling. Tissue morphology and composition were assessed 
by histological stains including Haematoxylin and Eosin, Safranin-O, and Picrosirius red.  
Finally, vascular growth was observed by histology and quantified by microCT 
angiography.  
RHBMP-2 DELIVERY 
Local rhBMP-2 delivery has proven a successful treatment strategy for spinal 
fusions and compound tibial fractures in the clinic, and has been demonstrated to 
stimulate functional repair of large bone defects in numerous animal models. However, 
minimizing the clinically reported side effects and high costs associated with current 
growth factor delivery systems remains challenging. Implementation of biomaterial 
delivery strategies that reduce the necessary effective dose would ameliorate these 
limitations and improve the clinical treatment of large bone defects.  
The study described in chapter III characterized and evaluated a hydrogel-based 
protein delivery system recently established in our laboratory. These experiments 
quantified the rhBMP-2 dose-response relationships and temporal release properties of 
this delivery system in comparison to the clinically used collagen sponge and 
demonstrated that the mesh/alginate delivery system improved bone formation over 
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current rhBMP-2 delivery methods. This highlights the importance of quantification of 
release kinetics and scaffold degradation properties for evaluating novel recombinant 
protein carriers. 
The largest dose evaluated in this study, 5 µg, has been shown in the 
mesh/alginate system to yield mechanical properties which exceed or are not significantly 
different from intact age-matched bone properties. In fact, we performed a pilot study in 
which the fixation plate was removed at week 22 post-surgery, and the animal continued 
to ambulate normally for another 8 weeks without incident. These observations 
demonstrate the functional efficacy of this protein/delivery system combination. 
One potential limitation of the alginate-based delivery system is that while the 
degree of alginate fragmentation increased with increasing protein dose, the gel did not 
completely degrade over the time course of the study. Indeed, in the plate-removal pilot 
study, in which histological analysis was delayed until week 30 post-surgery, residual 
alginate remained in the defect, despite uniform remodeling of the new bone to a lamellar 
microstructure (Figure 6.1). Some amount of marrow reconstitution was evident; 
however, substantial amounts of alginate gel were also present and encompassed by 





Figure 6.1. H&E stained section of segmental defect at week 30 post-surgery. The 
fixation plate was removed at week 24, allowing 8 weeks of normal ambulation on the 
regenerated bone. Some amount of marrow reconstitution was evident (dark region at left 
center of defect); however, alginate gel (pink) was also present and encompassed by 
trabecular-like lamellar bone (red). Images at 4x. 
 
Despite 8 weeks of full weight-bearing after the completion of bone formation, 
the bone did not remodel to a native cortical architecture. Similarly, allowing load 
transfer during the stage of active bone formation but after defect bridging as 
demonstrated in Chapter IV also failed to restore cortical bone architecture. One 
explanation is that the residual alginate hydrogel may have interfered with the remodeling 
process, preventing cortical bone restoration. This is corroborated by comparison of the 
current study with a previous study in which the volume of alginate delivered to the 
defect was 150 µl. In the current dose-response study, the volume of alginate was 200 µl 
with the goal of limiting the error in the dose delivered due to over- or under-injecting. 
This however, resulted in a higher volume of residual alginate at week 12 and a 
significantly lower maximum torque at failure in the 200 µl defects. It is therefore 
hypothesized that residual alginate may interfere with mechanical integration, suggesting 
that minimizing residual alginate volume and increasing the degradation kinetics may 
further enhance functional restoration. 
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Future work will therefore aim to develop improved hydrogel delivery systems 
that feature sustained delivery, but will degrade rapidly following protein release to 
facilitate reconstitution of native cortical bone architecture. One attractive alternative to 
alginate is the polyethylene glycol (PEG) hydrogel. PEG hydrogels provide extensive 
tailorability of degradation kinetics by incorporation of cleavable peptides, as well as 
allowing covalent biofunctionalization with adhesive motifs and therapeutic proteins 
[222]. Such an approach may allow tight control of growth factor presentation and release 
as well as degradation kinetics to facilitate integration and remodeling. Future studies 
will compare the release and degradation properties and bone regeneration capacity of 
other hydrogel-based delivery systems with the alginate gel described here.  
An alternative explanation for the failure to remodel to native cortical architecture 
is that rat bone does not feature secondary remodeling (i.e. osteonal, BMU-based cutting 
cones) as in large animals and humans. As a result, extensive reconstruction of 
architectural features over the time course of these studies may not be feasible in the rat 
model. Therefore, currently ongoing ovine studies will assess the nanofiber mesh/alginate 
delivery of rhBMP-2 in a critically-sized 3 cm tibial defect in the sheep (Figure 6.2). 
These studies, conducted in collaboration with Dr. Dietmar Hutmacher at the Queensland 
University of Technology in Brisbane, Australia will investigate the efficacy of the 
mesh/alginate delivery system in a similar sized defect to those found in humans, and will 




      
Figure 6.2. Ongoing sheep bone defect study: critically-sized 3 cm defect in the sheep 
tibia (A), with electrospun nanofiber mesh placed around the defect (B). 
 
 In Chapter V, the effect of rhBMP-2 on vascular growth was indirectly evaluated, 
demonstrating increased vascular network formation with an increased dose of rhBMP-2.  
Future experiments will study vascular network formation in empty and scaffold-only 
defects to evaluate the role of rhBMP-2 and bone formation on vascular growth.  Large 
differences in vascular morphology, distribution, and orientation were also seen at week 3 
post-surgery between treated defects and unoperated age-matched controls.  Future 
studies will evaluate later time points to assess the extent and time course of vascular 
remodeling in large bone defects treated with sustained delivery of rhBMP-2. 
EFFECTS OF MECHANICAL LOADING 
Chapters IV and V evaluated the effects of in vivo mechanical loading on bone 
formation and neovascular growth. The study described in chapter IV first demonstrated 
that functional transfer of axial loads by modulation of fixation plate stiffness 
significantly alters BMP-mediated large bone defect repair by increasing bone formation 
and distribution and modulating tissue organization and differentiation. The study 
described in Chapter V then demonstrated that the timing of load application significantly 




bone formation and delayed loading enhancing bone formation and vascular network 
remodeling. Together, these data indicate that consideration and modulation of the 
mechanical environment may improve clinical treatment of challenging segmental bone 
defects as well as advance our understanding of the role of biomechanical factors in bone 
tissue differentiation, formation, and remodeling. 
The results described here have several similarities with the response of bone 
fractures to mechanical loading, though key differences are also evident. As in fracture 
healing, mechanical loading altered the tissue differentiation profile and increased and 
prolonged the chondral phase of endochondral ossification [97, 102, 110, 140]. Also, like 
fracture healing, the early phase of healing was highly sensitive to mechanical conditions, 
and excessive motion resulted in development of nonunion [103, 110, 139, 149, 250]. 
However, large bone defect healing differs from canonical fracture healing, in that the 
defects are critically-sized and will not heal without intervention. Besides providing a 
more challenging model to evaluate the efficacy of various treatment strategies, this may 
change the response to mechanical conditions. In fracture healing, early loading has been 
shown to stimulate both vascular growth [250] and bone formation [107], however the 
small size of the gap may prevent the large deformations seen in the present early loading 
study. In large bone defect healing, without sufficient biological stimulus to induce bone 
formation, the tissue may be particularly sensitive to the magnitude of interfragmentary 
strains. The potential for low or moderate deformations to enhance the early stages of 
defect healing have not been evaluated. Future studies will assess the effects of early 
loading using a modified compliant fixation plate which features an increased axial 
stiffness to decrease interfragmentary strains. This can be accomplished easily by 
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increasing the stiffness of the elastomer segments or by changing the plate geometry. A 
possible limitation of the clinical applicability of this work is that with internal fixation, 
plate actuation requires a secondary surgical intervention. These limitations may be 
addressed by use of external fixators such as the Ilizarov ring system, which remains a 
popular fixation device for such defects, or use of internal fixation plates with time-
variable stiffness by incorporation of degradable segments. 
However, preliminary studies (data not shown) suggested that without sufficient 
rhBMP-2 to cause defect bridging, mechanical loading failed to enhance repair, likely as 
a result of large deformations as observed in the early loading study. Future experiments 
will therefore directly evaluate delayed loading with a low dose of BMP to determine 
whether defect bridging prior to load application is required for an anabolic effect or 
whether loading can overcome an insufficient biological stimulus. 
 Ongoing studies are investigating the cellular and molecular mechanisms of 
BMP-mediated bone regeneration and mechanical loading through 
immunohistochemistry. Histological analysis has highlighted the dense presence of 
osteocytes in newly formed bone matrix, and these cells may be responsible for 
coordination of mechano-adaptive processes [40]. Immunostaining will be therefore 
conducted to localize markers of bone modeling and remodeling, including osteoblastic 
differentiation (osteocalcin, osteopontin), matrix production (pro-collagen I), and 
osteoclast activity (tartrate-resistant acid phosphatase - TRAP), as well as blood vessel 
formation and remodeling (CD31/PECAM-1, Ang-2), and inflammation (CD14, CD68, 
IL10). These studies will allow investigation of the interactions between the time course 
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of angiogenesis, inflammation and early osteoblast activity to better understand the stages 
of bone defect repair and the proper timing of protein delivery and load actuation. 
Also, in collaboration with Dr. Georg Duda and Dr. Peter Fratzl at the Julius 
Wolff Institute in Berlin, Germany, we are currently investigating the local effects of 
vascularization on mineralization and nanostructure by quantifying the orientation and 
size of mineral crystals near to and far away from blood vessels, both in the mature intact 
bone of the proximal and distal femur and in the newly-formed bone in the bone defect, 
under both stiff and compliant fixation. These studies will employ the small-angle X-ray 
scattering technique developed by our collaborators [339-340].  
Future studies will also examine the effects of mechanical loading on limbs 
treated with collagen sponge delivery of rhBMP-2. Because this scaffold degrades 
rapidly, the effect of loading on gross bone remodeling may be enhanced, and may allow 
load-mediated restoration of a cortical architecture, which is not observed in the stiff 
plate samples with collagen sponge and rhBMP-2. Other studies will examine the 
interactions of bone formation and vascular growth with surrounding musculature. In the 
present studies, the orientation of blood vessels migrating into the defects suggested that 
much of the vascular supply originated in the surrounding musculature. This may provide 
insight for the development of therapies that stimulate the surrounding soft tissues to 
enhance bone regeneration. 
A primary limitation of the methodology chosen for application of mechanical 
loading to the regenerating limbs is that the mechanical environment was not explicitly 
controlled. Loads were not externally applied to the femur; rather, loading was passively 
applied by the impact and muscle contraction forces associated with normal cage 
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ambulation. In these studies, all animals received bilateral defects, with the contralateral 
limb receiving a stiff fixation plate. There is a possibility that the differences in stiffness 
between the plates could cause the animal to preferentially place more weight on one 
limb than the other, resulting in differential healing than would be found in unilateral 
defects. This effect has been observed previously in sheep models of fracture healing 
(personal communication with Dr. Georg Duda; data unpublished). However, we have 
previously shown that in this model, creation of a bone defect and implantation of a 
fixation plate results in no significant decrease in limb usage or gait parameters, as 
determined by catwalk analysis [341]. Future studies will therefore evaluate unilateral 
defects and assess gait function to evaluate the differences in load bearing between the 
two groups. 
Also, in these studies, we assumed that the femoral loads equaled the body 
weight. A recent modeling study, which evaluated both impact and muscle contraction 
loading, reported that femoral loads in rat bone reach 6-times the body weight during 
normal gait [342]. This would suggest higher magnitude boundary conditions than those 
reported here. However, we have recently demonstrated that the presence of an internal 
fixation plate reduces the maximal force capable by the biceps femoris muscle by 68% 
[343]. Together these suggest that the boundary conditions used are similar to those 
found in vivo. While some uncertainty is incurred, a sensitivity analysis determined that 
an order-of-magnitude variation in femoral load did not alter the comparisons of local 
strain distributions or relative strain magnitudes between the stiff and compliant plates. 
Future studies will employ several approaches to addressing these limitations 
using (1) the current loading model, (2) a modified rat model, and (3) a large animal 
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model. First, using the current ambulatory loading model, we aim to indirectly modulate 
the magnitude and frequency of loading by exposing the animals to controlled regimens 
of physical exercise. This will be conducted using two approaches: trained wheel running 
and forced swimming in a current pool as conducted previously in our lab by Duvall et al. 
[326]. The use of both the running and swimming regimes will allow comparison of 
combined impact and muscle contraction loading with muscle loading only. 
Second, to accurately control the applied loading, we will employ an external 
fixation device, rather than internal fixation, to which controlled loads will be applied by 
an external mechanical loading system. This approach has been explored previously for 
fracture healing studies [102], and will investigate the various effects of timing, 
magnitude, frequency, and loading mode (i.e. compression, tension, bending, etc.). To 
further isolate the applied loads, tail suspension can be implemented to remove all non-
specified loads and fully describe the mechanical history.  
Finally, due to size constraints in the rat model, it is difficult to measure 
mechanical conditions; however, in the forthcoming sheep studies, direct measurement of 
interfragmentary strains will be conducted using transcutaneous markers as performed 
elegantly by Duda and colleagues [105, 109]. This will allow use of the more clinically-
relevant patient-induced loading, but will provide real time measurement of mechanical 
boundary conditions. Together, these further experiments will provide insight into the 
therapeutic window of local stress/strain magnitudes, frequencies, and modes, with the 
goal to improve bone defect fixation strategies and physical therapy recommendations for 
clinical treatment of large bone defects. 
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Independent of bone formation and bone defects, the effects of matrix 
deformations on neovascular growth and angiogenesis remain an interesting question, 
with application in tissue engineering and cancer growth and metastasis. The effects of 
mechanical conditions on vascular network growth and remodeling are complex and 
varied. Several in vitro systems have attempted to assess the effects of matrix 
deformations on endothelial cells in 3D culture [322-323, 338], but a model system for 
applying known mechanical deformations to vascular networks in vivo has not yet been 
developed, to our knowledge. Such a tool could greatly enhance our understanding of the 
mechanoregulatory mechanisms that govern post-natal angiogenesis and network 
remodeling.  
Future work will therefore develop and characterize a subcutaneous loading 
chamber angiogenesis model (Figure 6.3) to isolate the neovascular response to 
controlled mechanical deformation in the absence of concurrent bone growth. Several 
models are commonly used to study post-natal angiogenesis [344-347]. One of the most 
frequent is the subcutaneous Matrigel® assay [348-352]. Matrigel is a mixture of 
extracellular and basement membrane proteins extracted from the mouse Engelbreth-
Holm-Swarm sarcoma and has been shown to simulate endothelial cell differentiation 
and tube formation [346, 353]. We have chosen to modify the Matrigel chamber assay 














Figure 6.3. Custom-made angiogenesis loading chamber.  The base and top platen are 
constructed of radiolucent polysulfone, and have 0.5mm diameter holes for vessel 
ingrowth. A movable crosshead can be screwed into the top platen via the center hole to 
actuate loading and the base stabilized by clamping onto the side channels. The overall 
dimensions are 14mm Ø x 5mm height. The internal volume is approximately 250µl. (A): 
CAD assembly. (B): Photograph of prototype with set screw and top screw indicating 
loading arm attachment location. (C): Exploded view showing chamber interior and 
porosity.  
 
Experiments will evaluate the effects of different modes and magnitudes of 
loading on new blood vessel networks. Initially, pilot studies will be conducted to 
determine a proper formulation for an angiogenesis-supporting matrix, and to determine 
the necessary doses of angiogenic growth factors such as FGF and VEGF to stimulate 
blood vessel network formation. After determination of a dose of angiogenic growth 
factors that will result in robust angiogenesis and confirmation that these vessels can be 
quantified by microCT angiography, that dose will be selected to create constructs that 
will be exposed to tensile and compressive deformations. We hypothesize that there will 
be a biphasic load-response profile in which moderate stretching of a subcutaneous 
vascular network will enhance vascular remodeling to modulate vessel size, number, and 







In conclusion, these data describe the rhBMP-2 dose-response relationships and 
temporal release properties of a hybrid alginate-based protein delivery system in 
comparison to the clinically-used collagen sponge and demonstrate that this system 
improves bone formation over current delivery methods. This work highlights the 
importance of quantification of release kinetics and scaffold degradation properties for 
evaluating novel recombinant protein carriers. These data also demonstrate that, while 
sensitive to timing, in vivo mechanical loading can enhance large bone defect 
regeneration and modulate vascular growth and remodeling. Together, these observations 
suggest that controlled modulation of the biochemical and biomechanical environments 
may improve clinical treatment of challenging bone defects. 
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 This appendix describes the development of the uniaxially compliant fixation 
plates used in this thesis as well as previous designs which, despite showing promise for 
developing models of hypertrophic nonunion, were not suitable for mechanical 
stimulation of bone formation.  These studies featured delivery of rhBMP-2 using 
structural poly-lactic acid scaffolds in combination with alginate hydrogel. 
Methods 
Compliant Fixation Plate Development: 
To achieve load transfer from the plate to the construct, the standard plates 
described previously [275] were first modified by incorporating a full-thickness segment 
of silicone elastomer (RTV Silicone Adhesive, Factor II, Inc., Lakeside, AZ) (Figures 
A.1(a) and A.1(b)). This design was multiaxially compliant, possessing a low stiffness in 
response to multiple loading modes – axial, bending, torsion and shear.  A second design 
allowed only axial deformation of the defect under ambulatory loads by constraining the 
stainless steel plates which were fixed to the bone to slide with respect to the polysulfone 
plate bridging the defect (Figures A.1(c) and A.1(d)). A finite axial stiffness was effected 
by incorporating the silicone elastomer between the steel and polysulfone plates. A 




 This section is modified from Boerckel et al. “In vivo Model for Evaluating the Effects of Mechanical 
Loading on Tissue-Engineered Bone Repair.” Journal of Biomechanical Engineering 2009 (reference 274). 
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removable stainless steel clip served as a locking system that allowed elective actuation 
of load-sharing. 
 
Figure A.1. Fixation Plate designs. (a) Standard plate, (b) multiaxially compliant plate, 
(c) unactuated uniaxially compliant plate, (d) actuated uniaxially compliant plate. 
Removal of the rigid clip actuates the uniaxial plate, allowing load transduction through 
the elastomer (in blue). 
 
 In the first study, femurs were stabilized by the standard fixation (std.) plate 
described previously. In experimental limbs, the standard plates were replaced in a 
second surgery at 8 weeks post-surgery with the multiaxially compliant (multi.) plates.  
In the second study, experimental limbs were stabilized by the axially compliant 
(axial) plates. At the time of implantation, the axial plates were constrained to prevent 
motion and were actuated at week 4 post-implantation by surgical removal of the clip.  
Fixation Plate Mechanical Characterization 
Characterization of axial, flexural, and torsional plate stiffness was performed by 
affixing the plates to age-matched excised femurs and potting the epiphyses in Wood‟s 
metal (Alfa Aesar, Ward Hill, MA). Axial tests were conducted with and without a 
hydrated scaffold placed in the defect, and were performed under displacement control at 
a rate of 0.01 mm/sec to a displacement of 1 mm. Torsional tests were conducted under 
angular displacement control to a rotation of +/- 5 degrees at a rate of 0.1 deg/sec. 
Finally, three-point bending tests were conducted for the standard and axially-compliant 
plates under displacement control to a maximum deflection of 0.5 mm at a rate of 0.02 
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mm/sec. The multiaxially compliant plates were tested in four-point bending to a 
maximum displacement of 1mm at a rate of 0.05 mm/sec. Standard beam bending theory 
was used to calculate the average flexural stiffness of each plate from the recorded loads 
and deflections.   
Scaffold Production: 
Poly(L-lactide-co-D,L-lactide 70:30)/tri-calcium phosphate (PLDL-TCP) 
scaffolds were produced with longitudinally-oriented porous microarchitecture as 
previously described [354]. Briefly, 100 micron diameter removable fibers coated with 
medical grade PLDL combined with 10% TCP, by weight, and the porogen 
azodicarbonamide were used to create longitudinal pores, followed by decomposition of 
the porogen at 260 
o
C resulting in a random microporosity. The scaffolds were cut to size 
(4mm diameter x 8mm length with 1.5mm diameter core) and sterilized by gamma 
irradiation (2.5 Mrad).  
Growth Factor Loading 
Each scaffold was coated with 25µg/mL rat plasma fibronectin (F0635; Sigma-
Adlrich, St. Louis, MO) to improve cellular adhesion, and then loaded with bone 
morphogenetic protein 2 (BMP-2) (355-BM/CF, R&D Systems, Minneapolis, MN) using 
a previously described protocol [275]. Briefly, the protein was reconstituted in 2% RGD-
functionalized alginate, which was pipetted into the scaffold and crosslinked by bathing 
in CaCl2. Each scaffold received a volume of 50 µL of RGD-alginate containing 2 µg 
BMP-2. 
Animal model & analysis techniques 
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Rat segmental defects were created and evaluated by Faxitron, microCT, and 
mechanical testing as described previously (see Chapter III, IV, and V).  
Finite Element Modeling 
MicroCT image-based finite element models of the defect and ingrown tissues at 
four weeks post-surgery were created to predict tissue-level stress and strain distributions 
resulting from estimated ambulatory loads. One animal was sacrificed at four weeks post-
surgery and a femur was excised, mechanically tested in axial compression, and scanned 
at medium resolution with an isometric voxel size of 21µm. Images thresholded for both 
bone and soft tissues/scaffold material were concatenated and then voxels were converted 
directly to finite elements. By assigning the newly-formed bone a local modulus of Ebone 
= 2 GPa and comparing the effective axial stiffness of the model to the measured value 
determined by mechanical testing of that same femur, the soft tissue and scaffold 
modulus, Est, could be estimated. 
Results 
Fixation Plate Characterization 
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Table A.1. Fixation plate mechanical characterization. All values given as mean ± std. 
deviation.  
  Standard Plate Multiaxial Plate 
Uniaxial Plate  
Actuated Unactuated 
Axial Stiffness (k) 
without scaffold 
[N/mm] 
214.3 ± 4.1 9.58 ± 2.95 8.4 ± 0.4 349.5 ± 35.1  
Axial Stiffness (k) 
with scaffold 
[N/mm] 




14.8 ± 1.61 0.802 ± 0.133  6.95 ± 0.18 9.14 ± 2.94 
Flexural Rigidity 
(EI) concave     [N-
mm^2] 
29236.3 ± 260.8 146.3 ± 50.4 25688.3 ± 657.4  26938.7 ± 629.5  
Flexural Rigidity 
(EI) convex      [N-
mm^2] 
30472.0 ± 736.8 132.0 ± 29.0  28015.0 ± 2076.1 42392.0 ± 8350.1  
 
Mechanical characterization of the plates revealed that the axial compressive 
stiffness of the standard plates was 214.3 ± 4.1 N/mm (mean ± std. dev.) (Table 1). With 
a hydrated scaffold placed in the defect to approximate the day-zero mechanical 
environment, the effective stiffness increased by 19%. The axial stiffnesses of the 
multiaxial and actuated uniaxial plates were 3.9% and 4.5% of the standard plate 
stiffness, respectively. Actuation of the uniaxial plates by removal of the rigid clip 
reduced the axial stiffness by 97.6%. In comparison with the standard plate, the 
unactuated uniaxial plate was 58% and 63% stiffer with and without the scaffold, 
respectively. This indicates a higher degree of stress shielding in the experimental limbs 
prior to actuation. With the scaffold in place, the effective axial stiffness of the multiaxial 
and actuated uniaxial plates was increased 9.8- and 10.4-fold, respectively, demonstrating 
increased axial load transduction to the construct in the compliant plates.  
Though comparable to the actuated uniaxial plates in axial compression, the 
multiaxial plates were an order of magnitude less stiff than either the standard or uniaxial 
plates in torsion. The torsional stiffness of the multiaxial plates was 95% less than that of 
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the standard plate, while the actuated and unactuated uniaxial plates were 53% and 39% 
less stiff in torsion, respectively, compared to the standard plates.  
While the standard and uniaxial plates had comparable stiffness in response to 
bending loads, the multiaxial plates were 99.5% less stiff than either the standard or 
uniaxial plates in bending.  
As expected, therefore, mechanical testing revealed that in axial compression, the 
multiaxial plates and actuated uniaxial plates responded similarly and were significantly 
less stiff than either the standard plates or the unactuated uniaxial plates. In torsion and 
bending, the multiaxial plates were substantially less stiff than both the standard and 
uniaxial plates. 
Pilot Study 1: Multiaxial Plate 
Following implantation of the multiaxially compliant plates at 8 weeks post-
surgery (n=2), the shear and bending loads exerted during ambulation caused large 
deformations of the defect upon impact and the limbs re-straightened during the swing 
phase of the gait (Figure A.2), resulting in complete nonunion by week 12 (Figure A.3). 
This indicated that the multiaxially compliant plates were insufficiently stiff to prevent 
instability of the defect after 8 weeks of stable healing and precluded post-mortem CT 




Figure A.2. In vivo X-ray videography of rat ambulation with multiaxial plates. The low 
bending stiffness of the multiaxial plates resulted in large deformation of the limbs during 






Figure A.3. Faxitron images of multiaxial plates. Replacement of standard plates with 
multiaxial plates at 8 weeks post-surgery resulted in failure under shear and bending 




Pilot study 2: Uniaxial Plate 
As a result of these observations, the compliant plates were redesigned to allow 
only uniaxial deformations. The rationale was that shear deformations may be responsible 
for inducing failure, particularly at the scaffold-bone interface. The BMP-2 delivered 
within PLDL/TCP scaffolds induced formation of low density bone by 4 weeks within 
the defect region. Longitudinal Faxitron scans demonstrated that after actuation of the 
plate at week 4 post-surgery, the uniaxial plate maintained stability of the defect, and 
both the loaded sample and the contralateral standard control achieved bridging at 12 
weeks (Figure A.4).  
 
Figure A.4. Faxitron images of uniaxially compliant plate, actuated at week 4 post-
surgery, and contralateral standard plate. The uniaxially compliant plate successfully 
maintained stability of the defect over the 12 week implantation period. Both samples 






Figure A.5. Post-mortem microCT. (a) Images of center 7mm used for evaluation, (b) 
sectioned images to demonstrate internal architecture and connectivity, and (c) bone 
volume quantification over a constant VOI. Bone volumes were comparable for the two 
samples. Cut images demonstrate a more uniformly connected morphology in the 
uniaxial sample. 
 
Quantitative microCT analysis revealed that bone volume (BV) within the central 
volume of interest was 18.9% greater in the loaded sample (Figure A.5). Consistent with 
this increase in BV, post-mortem biomechanical testing indicated that the torsional 
strength and stiffness of the loaded construct were substantially greater than those of the 
contralateral standard control. The torsional stiffness and maximum torque were 25.6- 
and 3.9-fold greater in the stimulated limb compared to the control (Figure A.6). These 
properties were greater than those of age-matched intact femurs whose torsional stiffness 
and max torque were 0.030±0.001 N-m/deg and 0.31±0.02 N-m, respectively, indicating 
full functional regeneration of that limb. These values were also greater than those 
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previously achieved using the same model with standard fixation and this growth factor 
dose [275], suggesting a positive effect of loading on defect healing.  
 
Figure A.6. Post-mortem mechanical testing: (a) torsional stiffness and (b) maximum 
torque. Dotted lines represent average properties of age-matched intact femurs. The 
mechanical properties of the uniaxially loaded sample were 2460% and 293% greater 
than the sample fixated with the standard plate for stiffness and maximum torque, 
respectively. 
 
Finite Element Modeling 
Image-based finite element modeling of a femur, excised, scanned and tested at 4 
weeks post-surgery indicated an effective stiffness of 7.05 N/mm.  Back calculation of 
local tissue modulus by comparison of measured to computed effective stiffness indicated 
an average soft tissue/scaffold modulus of 0.7MPa. Under estimated physiologic loads, 
the average axial strain in the newly-formed bone was -0.09 µstrain and -3.8E4 µstrain in 
soft tissues/scaffold. FE simulation revealed low principle compressive strains in the in-
growing bone and high strain gradients in the soft tissue adjacent to newly formed bone 
(Figure A.7). Spatial gradients of strain have previously been postulated to drive local 




Figure A.7. Finite element modeling: (a) microCT image of bone growth at week 4, 
sectioned and (b) minimum principle strain distributions at week 4 under estimated 
boundary conditions at same section. FE modeling revealed high strain gradients in the 
soft tissue adjacent to newly formed bone within the implanted construct. 
 
Discussion 
The effects of mechanical loading on large bone defect regeneration have not yet 
been evaluated. To that end, a challenging rat segmental defect model has been modified 
to allow transduction of ambulatory loads to the ingrowing bone within the tissue-
engineered construct. Multiaxially compliant fixation plates with low stiffness in 
response to shear and bending loads failed to maintain defect stability and promote 
functional repair. The sample fixated with the uniaxially compliant plate allowed axial 
deformation of the scaffold under physiologic loads, while restricting bending and shear 
deformations to maintain stability of the defect. Preliminary results using this new in vivo 
model suggested positive effects of load-bearing on functional defect repair. Loading 
may influence the functional integration of a tissue-engineered construct by altering the 
amount, organization, or mineralization of newly formed bone. Upcoming studies will 
repeat this work with larger sample sizes to test this hypothesis.  
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APPENDIX B: PROTOCOLS 
B.1. ALGINATE PREPARATION & BMP RECONSTITUTION 
Materials: 
 rhBMP-2 (R&D Systems) 
 Sterile filtered 4 mM HCl 
 0.1% Rat Serum Albumin (RSA) 
 CaSO4 (Calcium sulfate – 325, mesh) 
 RGD-Alginate 
 Alpha-MEM 
 Sterile 50 ml conical tubes 
 Sterile syringe filters 
 10 ml syringe 
 Sterile 1ml syringes 
 Leuer-lock connectors 
 Leuer lock caps 
 Sterile drape 




 4mm HCl  
o Can make this up prior. 
o Sterile filter & keep hood-sterile 
 0.21 g/ml CaSO4 
o 5.25 g CaSO4 
o 25 ml DI H20 
o Autoclave on liquid cycle (shortest time ~15 min), with cap loose. Take 
out of autoclave asap to prevent evaporation. 
o Can autoclave this day before. 
 0.1% RSA 
o Add 1 mg RSA per ml 4mM HCl (make up at least ~5ml to allow for 
accurate measurement). 
o Sterile filter into 50 ml conical tube. 
o Make up just prior to use. 
 3% Alginate 
o Determine volume of Alginate needed (A3 below). Add 0.03g/ml (see A 
below) alginate to A3 ml alphaMEM. Do this slowly without vortexing or 
shaking. 
o Make up just prior to use. 
 100 ug/ml BMP-2 
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o 100 ul 4 mM HCl 
o 10 ug BMP 
o Use up 10ug or 50ug vials accordingly up to the necessary amount. 




1. Calculate total volume of BMP + alginate needed:  
 V = # defects * 0.150 ml/defect  
 V=_________ 
 Account for ~25% loss + extras for lost animals, etc. 
2. Calculate mass of alginate in final 2% solution 
 V ml * 0.02g/ml = A g alginate 
 A = ______________ 
3. Calculate volume of 3% alginate needed: 
 A g alginate / (0.03 g/ml alginate) = A3 ml 
 A3 = ______________ 
4. Make up 3% alginate solution to volume A3. 
 Tare scale with new sterile 50ml conical. 
 In hood, remove alginate from sterile conical and place into the weighing 
conical. 
 Weigh. Remove or add alginate in hood with sterile instruments until 
arrived at necessary amount. 
 Add A3 ml alphaMEM to A g alginate, slowly. Do not shake, invert, or 
vortex. 
5. Determine desired dose: D (ie. 5 ug/defect) 
 D = _____________ 
6. Calculate amount of BMP solution needed:  
 B = (D / (0.150 ml)*V) / 100 ug/ml  
 B = ______________ 
7. Make up BMP-2 solution at 100 ug/ml to volume B. 
8. Calculate amount of extra media needed: 
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 M = V - A3 – B 
 M = ______________ 
9. Calculate amount of CaSO4 needed: 
 C = V/25 
 C = ______________ 
10. Put on sterile gloves. 
11. Set out sterile drape in hood. 
12. Have assistant empty 1ml syringes, leuerlock connectors & caps onto drape. 
13. Mix A3, B, and M in between syringes, removing all bubbles at end. 
14. Mix this with C into a separate syringe. Do this rapidly, taking care not to let any 
bubbles in at the beginning. Some bubbles will form in the mixing process. The 
fewer the better. 
15. Place cap on and refrigerate at 4oC until use the next day. 




B.2. FLUOROPHORE TAGGING OF BMP 
Materials: 
 rhBMP-2 (R&D Systems) 
 4 mM HCl 
 100 mM NaPO4 (monobasic) pH 7.5 
 3 kd Millipore Amicon Ultra Centrifugal Filters (Cat # UFC500396) 
 Centrifuge 
 Phosphate buffered Saline (w/o Ca & Mg) 
 Visen Medical VivoTag-S 750 In vivo NIR fluorochrome label (Part # 10123 – 
1mg) 
 Zeba Spin Desalting Column (Thermo Scientific #89882) 
 
Solution Preparations: 
 4mm HCl 
o   
 100 ug/ml BMP-2 
o 100 ul 4 mM HCl 
o 10 ug BMP 
 100 mM NaPO4 
o 1.38 g NaPO4 
o 100 ml DI H20 
o pH to 7.5 using 3N NaOH 
 50 ug/ml fluorochrome label 
o 20 ml NaPO4  
o 1 mg label 
  
Procedure: 
1.  Make up BMP-2 solution 
2. Buffer exchange to NaPO4 
 Pipette BMP into 3kD microcentrifuge filter  
 Add 400 ul NaPO4 
 Centrifuge at 14000 g for 30 min. 
 Add 500 ul NaPO4 
 Centrifuge at 14000 g for 30 min. 
 Collect by centrifuging at 4000 g for 30 sec. with filter upside down into 
new tube – yields ~20 ul 
3. Add 80 ul 50 ug/ml label to BMP 
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a. This gives 6.67nM BMP and 40.8 nM label => 6.12 molar excess of dye. 
4. Incubate 4 hrs at room temp in dark. 
5. Exchange buffer to PBS through Zeba spin desalting column 
a. Remove bottom closure and loosen cap 
b. Place column in 1.5-2ml collection tube. 
c. Centrifuge at 1500 g for 1 minute to remove storage solution 
d. Place mark on side of column where compacted resin is slanted upward. 
Place column in the centrifuge with the mark facing outward in all 
subsequent steps. 
e. Add 300 ul of buffer (PBS) on top of resin bed. Centrifuge at 1500 g for 1 
min 
f. Repeat last step 3 additional times, discarding buffer from the collection 
tube. 
g. Place column in new collection tube, remove cap and apply 100 ul of 
sample to the top of the compacted resin bed. 
h. Centrifuge at 1500 g for 2 minutes to collect sample. Discard column after 
use. 
6. The BMP is now labeled. 
7. Use nanodrop to determine final BMP concentration (to 1 sig fig). 
8. Run ~2 ug labeled and unlabeled BMP in parallel lanes in SDS-PAGE gel to 
ensure protein is tagged and excess dye is eliminated. 




B.3. MICROCT ANGIOGRAPHY: RAT PERFUSION TECHNIQUE 
Materials: 
 0.9% normal saline 
 0.4% (m/v) papaverine hydrochloride (Sigma-Aldrich) in 0.9% saline 
(vasodilator) 
 Microfil MV-122 kit (yellow color lead chromate compound) 
(http://www.flowtech-inc.com) 
 10% neutral buffered formalin  
 properly labeled waste bottles for formalin waste 
 1 pair small surgical scissors, 1 pair large scissors, 2 hemostats, 1 small curved 
pair of forceps, additional instruments by personal preference 
 18 gauge (green) 2” long catheter (Terumo SurFlo) 
 needles 
 1ml slip tip and 30ml luer lock syringes  
 peristaltic pump  
 peristaltic pump tubing (Cole-Parmer Masterflex 96410-16) 
 small tubing for connecting pump tubing to catheter (Cole-Parmer 95802-02) 
 male and female luer lock connectors as needed 
 diaper pads 
 50ml conicals for mixing Microfil and harvesting legs 
 gauze and cotton swabs 
 2-0 needle-less suture 
 Super glue 




 0.9% normal saline (~150 ml/rat) 
9 g sodium chloride 
1000 ml DI water 
 0.4% Papavirin solution (~200 ml/rat) 
9 g sodium chloride 
4 g papaverine hydrochloride 
1000 ml DI water 
 10% neutral buffered formalin (~250 ml/rat) 
 contrast agent (make ~30 ml/rat) 
do not add catalyst until immediately before perfusing animal 
mix 9.5% catalyst, 66.7% MV (yellow) compound, 23.8% diluent 
(ie. 21ml MV, 7.5 ml diluents, 3 ml catalyst per animal) 





1. Set up the peristaltic pump, check the flow, and bleed all air out of the line using 
the saline solution. You may have to start flow by siphoning the saline through 
the tubing using a syringe. 
2. Induce anesthesia at 5% isoflurane in an induction chamber. 
3. Switch animal over to the face mask at 2% isoflurane. 
4. Check for pedal withdrawal reflex using the toe pinch. When this reflex is not 
observed, the animal has reached a deep surgical plane and the procedure can 
begin. 
5. Using needles, pin animals hands and feet to styrofoam. Legs should be as 
straight as possible. 
6. Using scissors, cut transversely through the skin & muscles just below the 
xyphoid process of the rib cage to expose the diaphragm.  
7. Gently cut the diaphragm, taking care not to puncture the heart or underlying 
vessels. 
8. Cut through the rib cage to allow opening of the chest cavity. A large hemostat 
can be used to help keep the chest cavity open by clamping to xyphoid and 
positioning the instrument as necessary. 
9. Carefully dissect the heart free of the connective tissue holding it to the rib cage. 
10. Using small blunt tip forceps, pass a piece of 2-0 suture behind the aorta.  
11. While the heart is still pumping, insert the 18g catheter into the left ventricle 
(apex of the heart). Blood should begin to back out of the catheter.  
12. Carefully advance the soft catheter end up into the ascending aorta while backing 
the needle out.  
13. Using a single loop with the 2-0 suture, constrict the aorta around the catheter 
within its lumen to prevent back-flow later in the perfusion process. Optionally, 
place a small amount of super glue at the insertion point for additional stability. 
14. Attach the connection tubing to the catheter, making sure to minimize any air in 
the tubing. 
15. Cut the inferior vena cava. 
16. Immediately, turn on the pump, pefusing with saline ~25-50 ml  
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17. Perfuse withpapaverine solution ~150-200 ml. Perfusion volume is an estimate. 
The goal is to perfuse until vessels are clear. The liver should blanch quite 
quickly. Skin can carefully be cut away on the leg for “windows” to inspect 
perfusion of the hind limbs. The tail tip can also be cut, but should be clamped 
with a hemostat after observation. Kidneys can be inspected to evaluate perfusion 
also. 
18. Clear with saline ~25-50 ml 
19. Perfuse with 10% NBF ~150-250 ml. Again, perfusion volume is an estimate. The 
goal is to perfuse until the extremities are fully fixed. Inflation of the lungs is an 
indicator of backflow in the system. After ~!00 ml, one may observe relative 
inflation of the GI system, which is not abnormal.  
20. Clear with Saline ~25-50 ml 
21. Mix MV-122 with diluent in a 50 ml conical tube. Then, addcatalyst, mix, and 
immediately transfer to a 30 ml syringe for injection. Exhaust as much air as 
possible from the syringe before attaching to tubing. 
22. Switch luer-lock connector from pump tubing to syringe, being careful to 
minimize induction of air to the system. Slowly perfuse the animal manually, 
taking care not to let the catheter back out. 
23. Store animal in 4C refrigerator overnight to allow the microfil to polymerize. 
24. Remove the hindlimbs and store in formalin for up to two weeks to fix the tissue. 
25. MicroCT scan to get composite image of bone and vasculature. 
26. Decalcify hindlimbs in Cal-Ex II for 2 weeks. Use only gentle agitation if any. 
Strong agitation will shake polymerized microfil out of the vessels. 
27. MicroCT scan to get vasculature alone. 
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APPENDIX C: FIXATION PLATE DRAWINGS 
C.1. STIFF FIXATION PLATE DRAWINGS 








C.2. COMPLIANT FIXATION PLATE DRAWINGS 




C.2.2 Steel Plate 
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